

TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the
 treatment of **hepatitis** B virus infections
 IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.
 PA G.D. Searle and Co., USA; Monsanto Co.
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-445
 CC 1-5 (Pharmacology)
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		
AB	A method is disclosed for the treatment of hepatitis B virus (HBV) infections, which comprises administering to the infected host an N-alkyl deriv. of 1,5-dideoxy-1,5-imido-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms. In examples, N-butyl-1,5-dideoxy-1,5-imino-D-glucitol was shown to suppress the secretion of HBV particles and to cause intracellular retention of HBV				
DNA	in both stably transfected HepG 2.2.15 cells and HBV-infected HepG 2 cells.				
ST	deoxynojirimycin deriv virucide hepatitis B				
IT	Virucides and Virustats (deoxynojirimycin alkyl derivs. for treatment of hepatitis B virus infections)				
IT	Virus, animal (hepatitis B, deoxynojirimycin alkyl derivs. for treatment of hepatitis B virus infections)				
IT	72599-27-0, N-Butyl 1-deoxynojirimycin RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (deoxynojirimycin alkyl derivs. for treatment of hepatitis B virus infections)				

=>

TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the
 treatment of **hepatitis** B virus infections
 IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.
 PA G.D. Searle and Co., USA; Monsanto Co.
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-445
 CC 1-5 (Pharmacology)
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		
AB	A method is disclosed for the treatment of hepatitis B virus (HBV) infections, which comprises administering to the infected host an N-alkyl deriv. of 1,5-dideoxy-1,5-imido-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms. In examples, N-butyl-1,5-dideoxy-1,5-imino-D-glucitol was shown to suppress the secretion of HBV particles and to cause intracellular retention of HBV				
DNA	in both stably transfected HepG 2.2.15 cells and HBV-infected HepG 2 cells.				
ST	deoxynojirimycin deriv virucide hepatitis B				
IT	Virucides and Virustats (deoxynojirimycin alkyl derivs. for treatment of hepatitis B virus infections)				
IT	Virus, animal (hepatitis B, deoxynojirimycin alkyl derivs. for treatment of hepatitis B virus infections)				
IT	72599-27-0, N-Butyl 1-deoxynojirimycin RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (deoxynojirimycin alkyl derivs. for treatment of hepatitis B virus infections)				

=>

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's
DWPI and DPCI
NEWS 10 Aug 23 In-process records and more frequent updates now in
MEDLINE
NEWS 11 Aug 23 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12 Aug 23 Adis Newsletters (ADISNEWS) now available on STN
NEWS 13 Sep 17 IMSworld Pharmaceutical Company Directory name change
to PHARMASEARCH

NEWS EXPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,
CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001

=> FILE reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's
DWPI and DPCI
NEWS 10 Aug 23 In-process records and more frequent updates now in
MEDLINE
NEWS 11 Aug 23 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12 Aug 23 Adis Newsletters (ADISNEWS) now available on STN
NEWS 13 Sep 17 IMSworld Pharmaceutical Company Directory name change
to PHARMASEARCH

NEWS EXPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,
CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001

=> FILE reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 26 SEP 2001 HIGHEST RN 358967-92-7
DICTIONARY FILE UPDATES: 26 SEP 2001 HIGHEST RN 358967-92-7

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> e deoxynojirimycin

E1	32	DEOXYNOJIRI/BI
E2	1	DEOXYNOJIRIMICIN/BI
E3	32 -->	DEOXYNOJIRIMYCIN/BI
E4	1	DEOXYNOMININE/BI
E5	1	DEOXYNON/BI
E6	1	DEOXYNONA/BI
E7	1	DEOXYNONACTIC/BI
E8	1	DEOXYNONADECA/BI
E9	1	DEOXYNONON/BI
E10	1	DEOXYNONONAMIDE/BI
E11	3	DEOXYNONULO/BI
E12	3	DEOXYNONULOSON/BI

=> s e1-e3

	32	DEOXYNOJIRI/BI
	1	DEOXYNOJIRIMICIN/BI
	32	DEOXYNOJIRIMYCIN/BI
L1	32	(DEOXYNOJIRI/BI OR DEOXYNOJIRIMICIN/BI OR DEOXYNOJIRIMYCIN/BI)

=> s 3tc

L2	10	3TC
----	----	-----

=> d l2 10

L2 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2001 ACS
RN 12229-05-9 REGISTRY
CN Hilgardite-3A (H2[Ca2(BO2)5Cl]) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Parahilgardite (7CI)
OTHER NAMES:
CN Hilgardite
CN Hilgardite-3A
CN **Hilgardite-3Tc**
DR 12046-96-7
MF B O2 . Ca . Cl . 2 H
AF B5 Ca2 Cl O10 . 2 H
CI MNS
LC STN Files: CA, CAOLD, CAPLUS

CM 1

CRN 156286-03-2

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 26 SEP 2001 HIGHEST RN 358967-92-7
DICTIONARY FILE UPDATES: 26 SEP 2001 HIGHEST RN 358967-92-7

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> e deoxynojirimycin

E1	32	DEOXYNOJIRI/BI
E2	1	DEOXYNOJIRIMICIN/BI
E3	32 -->	DEOXYNOJIRIMYCIN/BI
E4	1	DEOXYNOMININE/BI
E5	1	DEOXYNON/BI
E6	1	DEOXYNONA/BI
E7	1	DEOXYNONACTIC/BI
E8	1	DEOXYNONADECA/BI
E9	1	DEOXYNONON/BI
E10	1	DEOXYNONONAMIDE/BI
E11	3	DEOXYNONULO/BI
E12	3	DEOXYNONULOSON/BI

=> s e1-e3

	32	DEOXYNOJIRI/BI
	1	DEOXYNOJIRIMICIN/BI
	32	DEOXYNOJIRIMYCIN/BI
L1	32	(DEOXYNOJIRI/BI OR DEOXYNOJIRIMICIN/BI OR DEOXYNOJIRIMYCIN/BI)

=> s 3tc

L2	10	3TC
----	----	-----

=> d l2 10

L2 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2001 ACS
RN 12229-05-9 REGISTRY
CN Hilgardite-3A (H2[Ca2(BO2)5Cl]) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Parahilgardite (7CI)
OTHER NAMES:
CN Hilgardite
CN Hilgardite-3A
CN **Hilgardite-3Tc**
DR 12046-96-7
MF B O2 . Ca . Cl . 2 H
AF B5 Ca2 Cl O10 . 2 H
CI MNS
LC STN Files: CA, CAOLD, CAPLUS

CM 1

CRN 156286-03-2

CMF B O2 . Ca . Cl
CCI TIS

CM 2

CRN 22537-15-1
CMF Cl

Cl

CM 3

CRN 14100-65-3
CMF B O2

^-O- B=O

CM 4

CRN 7440-70-2
CMF Ca

Ca

7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d 12 8

L2 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2001 ACS

RN 134424-53-6 REGISTRY

CN Illite-3A

([Al1.75(Fe0-1Mg0-1)0.25]K0.75(Si3.5Al0.5)[(OH)0.5-1F0-0.5]2O10)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN Guembelite

CN Hydromuscovite

CN Hydrosericite

CN Illidromica

CN Illite

CN Illite-3A

CN Illite-3T

CN **Illite-3Tc**

MF Al . F . Fe . H O . K . Mg . O5 Si2 . O

AF Al2.25 F0-1 Fe0-0.25 H1-2 K0.75 Mg0-0.25 O11-12 Si3.5

CI MNS, TIS

SR CA

LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CEN, CIN, PIRA,

CMF B O2 . Ca . Cl
CCI TIS

CM 2

CRN 22537-15-1
CMF Cl

Cl

CM 3

CRN 14100-65-3
CMF B O2

^-O- B=O

CM 4

CRN 7440-70-2
CMF Ca

Ca

7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d 12 8

L2 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2001 ACS

RN 134424-53-6 REGISTRY

CN Illite-3A

([Al1.75(Fe0-1Mg0-1)0.25]K0.75(Si3.5Al0.5)[(OH)0.5-1F0-0.5]2O10)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN Guembelite

CN Hydromuscovite

CN Hydrosericite

CN Illidromica

CN Illite

CN Illite-3A

CN Illite-3T

CN **Illite-3Tc**

MF Al . F . Fe . H O . K . Mg . O5 Si2 . O

AF Al2.25 F0-1 Fe0-0.25 H1-2 K0.75 Mg0-0.25 O11-12 Si3.5

CI MNS, TIS

SR CA

LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CEN, CIN, PIRA,

TULSA

Component	Ratio	Component Registry Number
O5Si2	1.75	20328-07-8
O	1.25	17778-80-2
F	0 - 1	14762-94-8
HO	1 - 2	14280-30-9
K	0.75	7440-09-7
Mg	0 - 0.25	7439-95-4
Fe	0 - 0.25	7439-89-6
Al	2.25	7429-90-5

8 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d 12 5

L2 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2001 ACS

RN 178183-12-5 REGISTRY

CN Siderophyllite-3A ((Al2Si2)(Fe2Al)K[(OH)0.5-1F0-0.5]2O10) (9CI) (CA
INDEX

NAME)

OTHER NAMES:

CN Siderophyllite

CN Siderophyllite-3A

CN **Siderophyllite-3Tc**

MF Al . F . Fe . H O . K . O4 Si . O

AF Al3 F0-1 Fe2 H1-2 K O11-12 Si2

CI MNS, TIS

SR CA

LC STN Files: CA, CAPLUS

Component	Ratio	Component Registry Number
O	2	17778-80-2
O4Si	2	17181-37-2
F	0 - 1	14762-94-8
HO	1 - 2	14280-30-9
K	1	7440-09-7
Fe	2	7439-89-6
Al	3	7429-90-5

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

20.94

21.09

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

TULSA

Component	Ratio	Component Registry Number
O5Si2	1.75	20328-07-8
O	1.25	17778-80-2
F	0 - 1	14762-94-8
HO	1 - 2	14280-30-9
K	0.75	7440-09-7
Mg	0 - 0.25	7439-95-4
Fe	0 - 0.25	7439-89-6
Al	2.25	7429-90-5

8 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d 12 5

L2 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2001 ACS

RN 178183-12-5 REGISTRY

CN Siderophyllite-3A ((Al2Si2)(Fe2Al)K[(OH)0.5-1F0-0.5]2O10) (9CI) (CA
INDEX

NAME)

OTHER NAMES:

CN Siderophyllite

CN Siderophyllite-3A

CN **Siderophyllite-3Tc**

MF Al . F . Fe . H O . K . O4 Si . O

AF Al3 F0-1 Fe2 H1-2 K O11-12 Si2

CI MNS, TIS

SR CA

LC STN Files: CA, CAPLUS

Component	Ratio	Component Registry Number
O	2	17778-80-2
O4Si	2	17181-37-2
F	0 - 1	14762-94-8
HO	1 - 2	14280-30-9
K	1	7440-09-7
Fe	2	7439-89-6
Al	3	7429-90-5

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

20.94

21.09

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 27 Sep 2001 VOL 135 ISS 14
FILE LAST UPDATED: 26 Sep 2001 (20010926/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> e hepatitis

E1	1	HEPATITIE/BI
E2	1	HEPATITIIS/BI
E3	31704 -->	HEPATITIS/BI
E4	4	HEPATITISA/BI
E5	13	HEPATITISB/BI
E6	1	HEPATITISBX/BI
E7	9	HEPATITISC/BI
E8	1	HEPATITISG/BI
E9	1	HEPATITISRELATED/BI
E10	1	HEPATITISS/BI
E11	2	HEPATITISTHE/BI
E12	1	HEPATITISU/BI

=> s e3

L3 31704 HEPATITIS/BI

=> s hbv

L4 4491 HBV

=> s l1

L5 751 L1

=> s l2

L6 1070 L2

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 27 Sep 2001 VOL 135 ISS 14
FILE LAST UPDATED: 26 Sep 2001 (20010926/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> e hepatitis

E1	1	HEPATITIE/BI
E2	1	HEPATITIIS/BI
E3	31704	--> HEPATITIS/BI
E4	4	HEPATITISA/BI
E5	13	HEPATITISB/BI
E6	1	HEPATITISBX/BI
E7	9	HEPATITISC/BI
E8	1	HEPATITISG/BI
E9	1	HEPATITISRELATED/BI
E10	1	HEPATITISS/BI
E11	2	HEPATITISTHE/BI
E12	1	HEPATITISU/BI

=> s e3

L3 31704 HEPATITIS/BI

=> s hbv

L4 4491 HBV

=> s l1

L5 751 L1

=> s l2

L6 1070 L2

=> s 15 and 16
L7 16 L5 AND L6

=> d 17 1-16

L7 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 2001:617821 CAPLUS
DN 135:175348
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for
treating hepatitis virus infections
IN Mueller, Richard A.; Bryant, Martin L.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060366	A1	20010823	WO 2001-US4512	20010213
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-182362	P	20000214		

RE.CNT 9
RE

- (1) Block, T; NATURE MEDICINE 1998, V4(5), P610 CAPLUS
 - (2) Block, T; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1994, V91(6), P2235 CAPLUS
 - (3) Dwek, R; WO 9835685 A 1998 CAPLUS
 - (4) Mueller, R; WO 9940916 A 1999 CAPLUS
 - (5) Mueller, R; WO 0047198 A 2000 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 2001:396644 CAPLUS
DN 135:24671
TI Solid carriers for improved delivery of active ingredients in
pharmaceutical compositions
IN Patel, Manesh V.; Chen, Feng-jing
PA Lipocine, Inc., USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001037808	A1	20010531	WO 2000-US32255	20001122
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

=> s 15 and 16
L7 16 L5 AND L6

=> d 17 1-16

L7 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 2001:617821 CAPLUS
DN 135:175348
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for
treating hepatitis virus infections
IN Mueller, Richard A.; Bryant, Martin L.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060366	A1	20010823	WO 2001-US4512	20010213
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-182362	P	20000214		

RE.CNT 9

RE

- (1) Block, T; NATURE MEDICINE 1998, V4(5), P610 CAPLUS
- (2) Block, T; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1994, V91(6), P2235 CAPLUS
- (3) Dwek, R; WO 9835685 A 1998 CAPLUS
- (4) Mueller, R; WO 9940916 A 1999 CAPLUS
- (5) Mueller, R; WO 0047198 A 2000 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 2001:396644 CAPLUS
DN 135:24671
TI Solid carriers for improved delivery of active ingredients in
pharmaceutical compositions
IN Patel, Manesh V.; Chen, Feng-jing
PA Lipocine, Inc., USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001037808	A1	20010531	WO 2000-US32255	20001122
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6248363 B1 20010619 US 1999-447690 19991123
 PRAI US 1999-447690 A 19991123
 RE.CNT 4
 RE

- (1) Cho; US 4849227 A 1989 CAPLUS
- (2) Desieno; US 5573783 A 1996 CAPLUS
- (3) Harrison; US 4717569 A 1988 CAPLUS
- (4) Stetsko; US 5340589 A 1994 CAPLUS

L7 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:338762 CAPLUS

DN 134:362292

TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

IN Farr, Spencer

PA Phase-1 Molecular Toxicology, USA

SO PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-165398	P	19991105		
	US 2000-196571	P	20000411		

L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:300514 CAPLUS

DN 134:331617

TI Oil-in-water emulsion compositions for polyfunctional active ingredients

IN Chen, Feng-jing; Patel, Mahesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028555	A1	20010426	WO 2000-US28835	20001018
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 6248363 B1 20010619 US 1999-447690 19991123
 PRAI US 1999-447690 A 19991123

RE.CNT 4
 RE

- (1) Cho; US 4849227 A 1989 CAPLUS
- (2) Desieno; US 5573783 A 1996 CAPLUS
- (3) Harrison; US 4717569 A 1988 CAPLUS
- (4) Stetsko; US 5340589 A 1994 CAPLUS

L7 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2001 ACS
 AN 2001:338762 CAPLUS
 DN 134:362292
 TI Methods of determining individual hypersensitivity to a pharmaceutical
 agent from gene expression profile
 IN Farr, Spencer
 PA Phase-1 Molecular Toxicology, USA
 SO PCT Int. Appl., 222 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-165398	P	19991105		
	US 2000-196571	P	20000411		

L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2001 ACS
 AN 2001:300514 CAPLUS
 DN 134:331617
 TI Oil-in-water emulsion compositions for polyfunctional active ingredients
 IN Chen, Feng-jing; Patel, Mahesh V.
 PA Lipocine, Inc., USA
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028555	A1	20010426	WO 2000-US28835	20001018
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-420159 A 19991018

RE.CNT 6

RE

- (1) Bistrrian; US 4871768 A 1989 CAPLUS
- (2) Demichele; US 5661180 A 1997 CAPLUS
- (3) Demichele; US 6013665 A 2000 CAPLUS
- (4) Demichele; US 6130244 A 2000 CAPLUS
- (5) Demichele; US 6160007 A 2000 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:137173 CAPLUS

DN 134:178396

TI Synthesis, activity and formulations of pharmaceutical compounds for
 treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI IT 1999-MI1817 A 19990812

OS MARPAT 134:178396

L7 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:114972 CAPLUS

DN 134:163282

TI Preparation of long chain N-alkyl amino and imino alditols and
 oxa-derivatives as antiviral agents

IN Zitzmann, Nicole; Butters, Terry D.; Platt, Frances M.; Carrouee, Sandra;
 Jacob, Gary S.; Picker, Donald H.; Fleet, George W. J.; Dwek, Raymond A.

PA UK

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-420159 A 19991018

RE.CNT 6

RE

- (1) Bistrrian; US 4871768 A 1989 CAPLUS
- (2) Demichele; US 5661180 A 1997 CAPLUS
- (3) Demichele; US 6013665 A 2000 CAPLUS
- (4) Demichele; US 6130244 A 2000 CAPLUS
- (5) Demichele; US 6160007 A 2000 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:137173 CAPLUS

DN 134:178396

TI Synthesis, activity and formulations of pharmaceutical compounds for
 treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GE, GD, GE,				
	HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG,				
	MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN,				
	YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI IT 1999-MI1817 A 19990812

OS MARPAT 134:178396

L7 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:114972 CAPLUS

DN 134:163282

TI Preparation of long chain N-alkyl amino and imino alditols and
 oxa-derivatives as antiviral agents

IN Zitzmann, Nicole; Butters, Terry D.; Platt, Frances M.; Carrouee, Sandra;
 Jacob, Gary S.; Picker, Donald H.; Fleet, George W. J.; Dwek, Raymond A.

PA UK

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----

PI WO 2001010429 A2 20010215 WO 2000-US21732 20000810
 WO 2001010429 A3 20010816
 W: AU, BR, CA, CN, IN, JP, KR, US
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE
 AU 2001018401 A5 20010305 AU 2001-18401 20000810
 PRAI US 1999-148101 P 19990810
 US 2000-198621 P 20000420
 WO 2000-US21732 W 20000810
 OS MARPAT 134:163282

L7 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2001 ACS
 AN 2001:100967 CAPLUS
 DN 134:141721
 TI N-Substituted glucamine compounds for treating hepatitis virus infections
 IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.
 PA G.D. Searle & Co., USA
 SO PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008672	A2	20010208	WO 2000-US3816	20000214
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-119836	P	19990212		
	US 1999-119858	P	19990212		
OS	MARPAT 134:141721				

L7 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2001 ACS
 AN 2000:861473 CAPLUS
 DN 134:32972
 TI Porous drug matrixes containing polymers and sugars and methods of their
 manufacture
 IN Straub, Julie; Bernstein, Howard; Chickering, Donald E., III; Khatak,
 Sarwat; Randall, Greg
 PA Acusphere, Inc., USA
 SO PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000072827	A2	20001207	WO 2000-US14578	20000525
	WO 2000072827	A3	20010125		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

PI WO 2001010429 A2 20010215 WO 2000-US21732 20000810
 WO 2001010429 A3 20010816
 W: AU, BR, CA, CN, IN, JP, KR, US
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE
 AU 2001018401 A5 20010305 AU 2001-18401 20000810
 PRAI US 1999-148101 P 19990810
 US 2000-198621 P 20000420
 WO 2000-US21732 W 20000810
 OS MARPAT 134:163282

L7 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2001 ACS
 AN 2001:100967 CAPLUS
 DN 134:141721
 TI N-Substituted glucamine compounds for treating hepatitis virus infections
 IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.
 PA G.D. Searle & Co., USA
 SO PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008672	A2	20010208	WO 2000-US3816	20000214
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-119836	P	19990212		
	US 1999-119858	P	19990212		
OS	MARPAT 134:141721				

L7 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2001 ACS
 AN 2000:861473 CAPLUS
 DN 134:32972
 TI Porous drug matrixes containing polymers and sugars and methods of their manufacture
 IN Straub, Julie; Bernstein, Howard; Chickering, Donald E., III; Khatak, Sarwat; Randall, Greg
 PA Acusphere, Inc., USA
 SO PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000072827	A2	20001207	WO 2000-US14578	20000525
	WO 2000072827	A3	20010125		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-136323 P 19990527
 US 1999-158659 P 19991008
 US 1999-433486 A 19991104
 US 2000-186310 P 20000302

L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2001 ACS
 AN 2000:742057 CAPLUS
 DN 133:309791
 TI Synthesis, activity and formulations of pharmaceutical compounds for
 treatment of oxidative stress and/or endothelial dysfunction
 IN Del Soldato, Piero
 PA Nicox S.A., Fr.
 SO PCT Int. Appl., 140 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061541	A2	20001019	WO 2000-EP3239	20000411
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	IT 1999-MI752	A	19990413		
OS	MARPAT 133:309791				

L7 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2001 ACS
 AN 2000:742053 CAPLUS
 DN 133:310142
 TI Synthesis, activity and formulations of pharmaceutical compounds for
 treatment of oxidative stress and/or endothelial dysfunction
 IN Del Soldato, Piero
 PA Nicox S.A., Fr.
 SO PCT Int. Appl., 159 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061537	A2	20001019	WO 2000-EP3234	20000411
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-136323 P 19990527
 US 1999-158659 P 19991008
 US 1999-433486 A 19991104
 US 2000-186310 P 20000302

L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2000:742057 CAPLUS

DN 133:309791

TI Synthesis, activity and formulations of pharmaceutical compounds for
 treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061541	A2	20001019	WO 2000-EP3239	20000411
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI IT 1999-MI752 A 19990413

OS MARPAT 133:309791

L7 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2000:742053 CAPLUS

DN 133:310142

TI Synthesis, activity and formulations of pharmaceutical compounds for
 treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061537	A2	20001019	WO 2000-EP3234	20000411
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI IT 1999-MI753 A 19990413
OS MARPAT 133:310142

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 2000:725436 CAPLUS
DN 133:301171
TI Compositions and methods for improved delivery of ionizable hydrophobic
therapeutic agents
IN Chen, Feng-jing; Patel, Manesh V.
PA Lipocine, Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059475	A1	20001012	WO 2000-US7342	20000316
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-287043 A 19990406

RE.CNT 3

RE

- (1) Blair; US 4306981 A 1981 CAPLUS
- (2) Hauer; US 5342625 A 1994 CAPLUS
- (3) Story; US 4944949 A 1990 CAPLUS

L7 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 2000:573657 CAPLUS
DN 133:172150
TI Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for
treating

hepatitis virus infections
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.
PA G.D. Searle & Co., USA
SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047198	A2	20000817	WO 2000-US3768	20000214
	WO 2000047198	A3	20010215		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,			

PRAI IT 1999-MI753 A 19990413
OS MARPAT 133:310142

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 2000:725436 CAPLUS
DN 133:301171
TI Compositions and methods for improved delivery of ionizable hydrophobic
therapeutic agents
IN Chen, Feng-jing; Patel, Manesh V.
PA Lipocine, Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059475	A1	20001012	WO 2000-US7342	20000316
	W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		

PRAI US 1999-287043 A 19990406

RE.CNT 3

RE

- (1) Blair; US 4306981 A 1981 CAPLUS
- (2) Hauer; US 5342625 A 1994 CAPLUS
- (3) Story; US 4944949 A 1990 CAPLUS

L7 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 2000:573657 CAPLUS
DN 133:172150
TI Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for
treating
hepatitis virus infections
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.
PA G.D. Searle & Co., USA
SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047198	A2	20000817	WO 2000-US3768	20000214
	WO 2000047198	A3	20010215		
	W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,		

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-119722 P 19990212
US 1999-119856 P 19990212

OS MARPAT 133:172150

L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 1999:529023 CAPLUS
DN 131:165293
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for
treating hepatitis virus infections
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.
PA G.D. Searle & Co., USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940916	A1	19990819	WO 1999-US1874	19990212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9927595	A1	19990830	AU 1999-27595	19990212
	BR 9907882	A	20001017	BR 1999-7882	19990212
	EP 1061922	A1	20001227	EP 1999-908079	19990212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI					
PRAI	US 1998-23401	A	19980212		
	US 1998-74508	P	19980212		
	WO 1999-US1874	W	19990212		

OS MARPAT 131:165293

RE.CNT 9

RE

- (1) Bayer AG; EP 0449026 A 1991 CAPLUS
 - (3) G D Searle & Co; WO 9522975 A 1995 CAPLUS
 - (4) G D Searle & Co; EP 0367748 A 1990 CAPLUS
 - (5) G D Searle and Co; WO 9835685 A 1998 CAPLUS
 - (6) Meiji Seika Kaisha Ltd; EP 0350012 A 1990 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 1998:568726 CAPLUS
DN 129:197981
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in
combination therapy for treating hepatitis virus infections
IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-119722 P 19990212
US 1999-119856 P 19990212

OS MARPAT 133:172150

L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 1999:529023 CAPLUS
DN 131:165293
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for
treating hepatitis virus infections
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.
PA G.D. Searle & Co., USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940916	A1	19990819	WO 1999-US1874	19990212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9927595	A1	19990830	AU 1999-27595	19990212
	BR 9907882	A	20001017	BR 1999-7882	19990212
	EP 1061922	A1	20001227	EP 1999-908079	19990212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

FI

PRAI US 1998-23401 A 19980212
US 1998-74508 P 19980212
WO 1999-US1874 W 19990212

OS MARPAT 131:165293

RE.CNT 9

RE

- (1) Bayer AG; EP 0449026 A 1991 CAPLUS
 - (3) G D Searle & Co; WO 9522975 A 1995 CAPLUS
 - (4) G D Searle & Co; EP 0367748 A 1990 CAPLUS
 - (5) G D Searle and Co; WO 9835685 A 1998 CAPLUS
 - (6) Meiji Seika Kaisha Ltd; EP 0350012 A 1990 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2001 ACS
AN 1998:568726 CAPLUS
DN 129:197981
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in
combination therapy for treating hepatitis virus infections
IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9861692	A1	19980908	AU 1998-61692	19980212
	EP 1007058	A1	20000614	EP 1998-906475	19980212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 2001512462	T2	20010821	JP 1998-535987	19980212
PRAI	US 1997-41221	P	19970214		
	WO 1998-US3004	W	19980212		
OS	MARPAT 129:197981				

L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1998:331371 CAPLUS

DN 129:16395

TI Preparation of phenylstatine derivatives as retroviral protease inhibitors

IN Chang, Min S.; Getman, Daniel P.; Mueller, Richard A.; Ottinger, James C.;

Stolzenbach, James C.; Talley, John J.; Vazquez, Michael L.; Decrescenzo, Gary A.

PA G. D. Searle & Co., USA

SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 109,787, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750648	A	19980512	US 1994-253531	19940603
	WO 9506061	A1	19950302	WO 1994-US8697	19940809
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,				
TG	AU 9475186	A1	19950321	AU 1994-75186	19940809
	ZA 9406325	A	19950821	ZA 1994-6325	19940819
	IL 110724	A1	19990817	IL 1994-110724	19940819
PRAI	US 1993-109787		19930820		
	US 1994-253531		19940603		
	WO 1994-US8697		19940809		
OS	MARPAT 129:16395				

L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1994:153741 CAPLUS

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9861692	A1	19980908	AU 1998-61692	19980212
	EP 1007058	A1	20000614	EP 1998-906475	19980212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 2001512462	T2	20010821	JP 1998-535987	19980212
PRAI	US 1997-41221	P	19970214		
	WO 1998-US3004	W	19980212		
OS	MARPAT 129:197981				

L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1998:331371 CAPLUS

DN 129:16395

TI Preparation of phenylstatine derivatives as retroviral protease inhibitors

IN Chang, Min S.; Getman, Daniel P.; Mueller, Richard A.; Ottinger, James C.;

Stolzenbach, James C.; Talley, John J.; Vazquez, Michael L.; Decrescenzo, Gary A.

PA G. D. Searle & Co., USA

SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 109,787, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750648	A	19980512	US 1994-253531	19940603
	WO 9506061	A1	19950302	WO 1994-US8697	19940809
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN					
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,				
TG					
	AU 9475186	A1	19950321	AU 1994-75186	19940809
	ZA 9406325	A	19950821	ZA 1994-6325	19940819
	IL 110724	A1	19990817	IL 1994-110724	19940819
PRAI	US 1993-109787		19930820		
	US 1994-253531		19940603		
	WO 1994-US8697		19940809		
OS	MARPAT 129:16395				

L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1994:153741 CAPLUS

DN 120:153741
 TI Use of antiretroviral drugs for treatment of motor neuron diseases
 IN Westarp, Martin Egon; Kornhuber, Hans Helmut
 PA Germany
 SO Ger. Offen., 6 pp.
 CODEN: GWXXBX
 DT Patent
 LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4307883	A1	19930923	DE 1993-4307883	19930312
PRAI	DE 1992-4207863		19920312		

=> d 17 14 15 16 all

L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:568726 CAPLUS
 DN 129:197981
 TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy for treating hepatitis virus infections
 IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.
 PA G.D. Searle and Co., USA
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-70
 ICS A61K031-70; A61K031-445
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 33, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9861692	A1	19980908	AU 1998-61692	19980212
	EP 1007058	A1	20000614	EP 1998-906475	19980212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 2001512462	T2	20010821	JP 1998-535987	19980212
PRAI	US 1997-41221	P	19970214		
	WO 1998-US3004	W	19980212		
OS	MARPAT 129:197981				

AB Methods and compns. are provided for treating hepatitis virus infections in mammals, esp. humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixts. thereof, or immunomodulating/immunostimulating agents, or (2) administering

DN 120:153741
 TI Use of antiretroviral drugs for treatment of motor neuron diseases
 IN Westarp, Martin Egon; Kornhuber, Hans Helmut
 PA Germany
 SO Ger. Offen., 6 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4307883	A1	19930923	DE 1993-4307883	19930312
PRAI	DE 1992-4207863		19920312		

=> d 17 14 15 16 all

L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:568726 CAPLUS
 DN 129:197981
 TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy for treating hepatitis virus infections
 IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.
 PA G.D. Searle and Co., USA
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-70
 ICS A61K031-70; A61K031-445
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 33, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9861692	A1	19980908	AU 1998-61692	19980212
	EP 1007058	A1	20000614	EP 1998-906475	19980212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 2001512462	T2	20010821	JP 1998-535987	19980212
PRAI	US 1997-41221	P	19970214		
	WO 1998-US3004	W	19980212		
OS	MARPAT 129:197981				
AB	Methods and compns. are provided for treating hepatitis virus infections in mammals, esp. humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixts. thereof, or immunomodulating/immunostimulating agents, or (2) administering				

N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixts. thereof, and immunomodulating/immunostimulating agents. Prepn. of 1,5-(butylimino)-1,5-dideoxy-D-glucitol and of the corresponding tetraacetate is described.

ST dideoxyiminoglucitol deriv antiviral hepatitis virus; tetraacetate butyliminodideoxyglucitol prepn antiviral hepatitis virus; nucleoside dideoxyiminoglucitol deriv antiviral combination hepatitis; nucleotide dideoxyiminoglucitol deriv antiviral combination hepatitis; immunomodulator dideoxyiminoglucitol deriv antiviral combination hepatitis; immunostimulant dideoxyiminoglucitol deriv antiviral combination hepatitis

IT Nucleotides, biological studies
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (analogs, antiviral; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT Nucleoside analogs
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiviral; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT Antiviral agents
 Drug delivery systems
 Drug interactions
 Hepatitis B virus
 Hepatitis virus
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT 3056-17-5, Stavudine 7481-89-2, Dideoxycytidine **19130-96-2D**, 1,5-Dideoxy-1,5-imino-D-glucitol, N-substituted derivs. 25526-93-6 30516-87-1, AZT 36791-04-5 66341-18-2, Acyclovir triphosphate 69123-90-6, FIAC 69256-17-3 69655-05-6, Dideoxyinosine 72458-45-8 **72458-46-9** 73243-67-1 79206-10-3 **79206-12-5** 79206-20-5 79206-22-7 80860-82-8 **81117-34-2** 81117-35-3 81117-38-6 85326-06-3 87190-81-6 99876-43-4 106941-25-7, 9-(2-Phosphonylmethoxyethyl)adenine 111687-37-7, D-Carbocyclic-2'-deoxyguanosine 115249-95-1 121154-51-6 128985-11-5 131167-83-4 **134678-17-4**, 3TC 134680-32-3 137530-41-7 143491-54-7, FTC 147058-39-7 160963-03-1 211987-28-9 211987-29-0 211987-30-3 211987-31-4 211987-32-5 211987-33-6 211987-34-7 211987-35-8 211987-36-9 211987-37-0 211987-38-1 211987-39-2 211987-40-5 211987-41-6 211987-42-7 211987-43-8 211987-44-9 211987-45-0 211987-46-1 211987-47-2 211987-48-3 211987-49-4 211987-50-7 211987-51-8 211987-52-9 211987-53-0 211987-54-1 211987-55-2 211987-56-3 211987-57-4 211987-58-5 211987-59-6 211987-60-9 211987-61-0 211987-62-1
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT **72599-27-0P**
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (dideoxyiminoglucitol derivs. in combination therapy for treating

N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixts. thereof, and immunomodulating/immunostimulating agents. Prepn. of 1,5-(butylimino)-1,5-dideoxy-D-glucitol and of the corresponding tetraacetate is described.

ST dideoxyiminoglucitol deriv antiviral hepatitis virus; tetraacetate butyliminodideoxyglucitol prepn antiviral hepatitis virus; nucleoside dideoxyiminoglucitol deriv antiviral combination hepatitis; nucleotide dideoxyiminoglucitol deriv antiviral combination hepatitis; immunomodulator dideoxyiminoglucitol deriv antiviral combination hepatitis; immunostimulant dideoxyiminoglucitol deriv antiviral combination hepatitis

IT Nucleotides, biological studies
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (analogs, antiviral; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT Nucleoside analogs
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiviral; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT Antiviral agents
 Drug delivery systems
 Drug interactions
 Hepatitis B virus
 Hepatitis virus
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT 3056-17-5, Stavudine 7481-89-2, Dideoxycytidine **19130-96-2D**, 1,5-Dideoxy-1,5-imino-D-glucitol, N-substituted derivs. 25526-93-6 30516-87-1, AZT 36791-04-5 66341-18-2, Acyclovir triphosphate 69123-90-6, FIAC 69256-17-3 69655-05-6, Dideoxyinosine 72458-45-8 **72458-46-9** 73243-67-1 79206-10-3 **79206-12-5** 79206-20-5 79206-22-7 80860-82-8 **81117-34-2** 81117-35-3 81117-38-6 85326-06-3 87190-81-6 99876-43-4 106941-25-7, 9-(2-Phosphonylmethoxyethyl)adenine 111687-37-7, D-Carbocyclic-2'-deoxyguanosine 115249-95-1 121154-51-6 128985-11-5 131167-83-4 **134678-17-4**, 3TC 134680-32-3 137530-41-7 143491-54-7, FTC 147058-39-7 160963-03-1 211987-28-9 211987-29-0 211987-30-3 211987-31-4 211987-32-5 211987-33-6 211987-34-7 211987-35-8 211987-36-9 211987-37-0 211987-38-1 211987-39-2 211987-40-5 211987-41-6 211987-42-7 211987-43-8 211987-44-9 211987-45-0 211987-46-1 211987-47-2 211987-48-3 211987-49-4 211987-50-7 211987-51-8 211987-52-9 211987-53-0 211987-54-1 211987-55-2 211987-56-3 211987-57-4 211987-58-5 211987-59-6 211987-60-9 211987-61-0 211987-62-1
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT **72599-27-0P**
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (dideoxyiminoglucitol derivs. in combination therapy for treating

hepatitis virus infections, and deriv. prepn.)
 IT 131262-77-6P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections, and deriv. prepn.)
 IT 108-24-7, Acetic anhydride 123-72-8, Butyraldehyde **19130-96-2**, 1,5-Dideoxy-1,5-imino-D-glucitol
 RL: RCT (Reactant)
 (reaction; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections, and deriv. prepn.)

L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1998:331371 CAPLUS

DN 129:16395

TI Preparation of phenylstatine derivatives as retroviral protease inhibitors

IN Chang, Min S.; Getman, Daniel P.; Mueller, Richard A.; Ottinger, James C.;

; Talley, John J.; Vazquez, Michael L.; Decrescenzo,

PI 5,750,648
 SC USA

-part of U.S. Ser. No. 109,787, abandoned.

DT DE 4307883
 LA
 IC
 NCI
 CC A11930923

Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750648	A	19980512	US 1994-253531	19940603
	WO 9506061	A1	19950302	WO 1994-US8697	19940809
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,				
TG	AU 9475186	A1	19950321	AU 1994-75186	19940809
	ZA 9406325	A	19950821	ZA 1994-6325	19940819
	IL 110724	A1	19990817	IL 1994-110724	19940819
PRAI	US 1993-109787		19930820		
	US 1994-253531		19940603		
	WO 1994-US8697		19940809		
OS	MARPAT 129:16395				
GI					

hepatitis virus infections, and deriv. prepn.)
 IT 131262-77-6P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections, and deriv. prepn.)
 IT 108-24-7, Acetic anhydride 123-72-8, Butyraldehyde **19130-96-2**, 1,5-Dideoxy-1,5-imino-D-glucitol
 RL: RCT (Reactant)
 (reaction; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections, and deriv. prepn.)

L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1998:331371 CAPLUS

DN 129:16395

TI Preparation of phenylstatine derivatives as retroviral protease inhibitors

IN Chang, Min S.; Getman, Daniel P.; Mueller, Richard A.; Ottinger, James C.;

Stolzenbach, James C.; Talley, John J.; Vazquez, Michael L.; Decrescenzo, Gary A.

PA G. D. Searle & Co., USA

SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 109,787, abandoned.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K038-06


NCL 530331000

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750648	A	19980512	US 1994-253531	19940603
	WO 9506061	A1	19950302	WO 1994-US8697	19940809
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,			
VN		RW:	KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,		
TG	AU 9475186	A1	19950321	AU 1994-75186	19940809
	ZA 9406325	A	19950821	ZA 1994-6325	19940819
	IL 110724	A1	19990817	IL 1994-110724	19940819
PRAI	US 1993-109787		19930820		
	US 1994-253531		19940603		
	WO 1994-US8697		19940809		
OS	MARPAT 129:16395				
GI					



AB The present invention is directed to the prepn. and use of retroviral protease inhibitors I [R1 = CHMe2, CHMeEt, CMe3, CMe2SMe, CMe2S(O)Me, CMe2SO2Me; R2 = Me-L-Ala, Me-D-Ala, H-Gly, Me-Gly, H-L-Pro, H-D-Pro, H-L-Ile each optionally substituted on the nitrogen atom with benzyloxycarbonyl or tert-butoxycarbonyl], or a pharmaceutically acceptable salt or ester thereof, and combinations of retroviral protease inhibitors which are effective in preventing the replication of mammalian retroviruses, such as human immunodeficiency virus (HIV). Thus, coupling of N-benzyloxycarbonyl-N-methyl-L-alanine with reduced peptide mimic I

(R1 = CMe3; R2 = H) (prepd. in 7 steps from N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone, isoamylamine, tert-Bu isocyanate, and N-benzyloxycarbonyl-L-tert-butylglycine), followed by catalytic deprotection, gave 54% desired inhibitor I (R1 = CMe3, R2 = Me-L-Ala) (II). II inhibited HIV-infected cells with IC50 = 8 nM, and EC50 = 96 mg/mL in the presence of AZT or DDI.

ST phenylstatine deriv prepn retroviral protease inhibitor; reduced phenylalanine peptide prepn HIV inhibitor

IT Anti-AIDS drugs

Antiviral agents

Human immunodeficiency virus 1

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 168056-64-2P 168056-65-3P 168056-66-4P 168056-68-6P 168056-69-7P
168112-86-5P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 143577-34-8P 155662-50-3P 159910-86-8P 168056-54-0P 168056-55-1P
168056-56-2P 168056-57-3P 168056-58-4P 168056-59-5P 168056-60-8P
168056-61-9P 168056-62-0P 168056-63-1P 168056-67-5P 168056-70-0P
168112-84-3P 168112-85-4P 168112-87-6P 207614-10-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 7481-89-2, DDC 23339-47-1, DAT 30516-87-1, AZT 69655-05-6, DDI

72599-27-0, N-Butyl-1-deoxynojirimycin 79831-76-8,

Castanospermine 106941-25-7, PME A **134678-17-4**, 3TC

RL: BAC (Biological activity or effector, except adverse); THU


(Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 127943-39-9P

RL: BYP (Byproduct); PREP (Preparation)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)



AB The present invention is directed to the prepn. and use of retroviral protease inhibitors I [R1 = CHMe2, CHMeEt, CMe3, CMe2SMe, CMe2S(O)Me, CMe2SO2Me; R2 = Me-L-Ala, Me-D-Ala, H-Gly, Me-Gly, H-L-Pro, H-D-Pro, H-L-Ile each optionally substituted on the nitrogen atom with benzyloxycarbonyl or tert-butoxycarbonyl], or a pharmaceutically acceptable salt or ester thereof, and combinations of retroviral protease inhibitors which are effective in preventing the replication of mammalian retroviruses, such as human immunodeficiency virus (HIV). Thus, coupling of N-benzyloxycarbonyl-N-methyl-L-alanine with reduced peptide mimic I

(R1 = CMe3; R2 = H) (prepd. in 7 steps from N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone, isoamylamine, tert-Bu isocyanate, and N-benzyloxycarbonyl-L-tert-butylglycine), followed by catalytic deprotection, gave 54% desired inhibitor I (R1 = CMe3, R2 = Me-L-Ala) (II). II inhibited HIV-infected cells with IC50 = 8 nM, and EC50 = 96 mg/mL in the presence of AZT or DDI.

ST phenylstatine deriv prepn retroviral protease inhibitor; reduced phenylalanine peptide prepn HIV inhibitor

IT Anti-AIDS drugs
Antiviral agents

Human immunodeficiency virus 1

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 168056-64-2P 168056-65-3P 168056-66-4P 168056-68-6P 168056-69-7P
168112-86-5P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 143577-34-8P 155662-50-3P 159910-86-8P 168056-54-0P 168056-55-1P
168056-56-2P 168056-57-3P 168056-58-4P 168056-59-5P 168056-60-8P
168056-61-9P 168056-62-0P 168056-63-1P 168056-67-5P 168056-70-0P
168112-84-3P 168112-85-4P 168112-87-6P 207614-10-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 7481-89-2, DDC 23339-47-1, DAT 30516-87-1, AZT 69655-05-6, DDI
72599-27-0, N-Butyl-1-deoxynojirimycin 79831-76-8,
Castanospermine 106941-25-7, PME A **134678-17-4**, 3TC

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 127943-39-9P

RL: BYP (Byproduct); PREP (Preparation)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 63-91-2, L-Phenylalanine, reactions 107-85-7, Isoamylamine 541-88-8,
Chloroacetic anhydride 1118-68-9, N,N-Dimethylaminoacetic acid
1148-11-4 1609-86-5, tert-Butyl isocyanate 3182-95-4,

L-Phenylalaninol

3391-99-9 3392-08-3 4530-20-5 15761-39-4 21691-41-8,
N-Benzylloxycarbonyl-N-methyl-L-alanine 26049-94-5 62965-10-0
68223-03-0, N-Benzylloxycarbonyl-N-methyl-D-alanine 112898-22-3

RL: RCT (Reactant)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 111060-52-7P 111060-64-1P 111138-83-1P 127927-43-9P 128018-43-9P
128018-44-0P 143224-67-3P 143224-89-9P 143224-90-2P 143224-91-3P
143225-04-1P 168056-71-1P 168056-72-2P 168056-73-3P 168056-74-4P
168056-75-5P 168056-76-6P 168056-77-7P 168056-78-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 37205-61-1, Protease inhibitor

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL
(Biological study)

(retroviral; prepn. of phenylstatine derivs. as retroviral protease
inhibitors)

L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1994:153741 CAPLUS

DN 120:153741

TI Use of antiretroviral drugs for treatment of motor neuron diseases

IN Westarp, Martin Egon; Kornhuber, Hans Helmut

PA Germany

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-70

ICS A61K031-55; A61K031-505; A61K031-66; A61K031-445; A61K031-47

ICI A61K031-70, A61K031-55, A61K031-505, A61K031-66, A61K031-445, A61K031-47

CC 1-11 (Pharmacology)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI DE 4307883	A1	19930923	DE 1993-4307883	19930312
---------------	----	----------	-----------------	----------

PRAI DE 1992-4207863		19920312		
----------------------	--	----------	--	--

AB Nucleoside analogs and other antiretroviral agents are useful for
treatment of diseases of motor neurons, such as amyotrophic lateral
sclerosis (ALS), spinal muscular atrophy, and progressive bulbar
paralysis. Thus, administration of zidovudine (500 mg/day orally for

2-10

mo) to ALS patients reversed the elevation in serum creatine kinase level
characteristic of ALS in 8 of 10 patients.

ST motor nerve disease treatment virucide; amyotrophic lateral sclerosis
retrovirus drug; zidovudine nerve disease

IT Virucides and Virustats

(for retroviruses, motor neuron disease treatment with)

IT Ribonucleic acids, viral

RL: BIOL (Biological study)

(of retrovirus, antisense, motor neuron disease treatment with)

IT Virus, animal

(Maedi-Visna, antisense RNA of, motor neuron disease treatment with)

IT Paralysis

(bulbar, progressive, treatment of, with retrovirus inhibitors)

IT 63-91-2, L-Phenylalanine, reactions 107-85-7, Isoamylamine 541-88-8,
Chloroacetic anhydride 1118-68-9, N,N-Dimethylaminoacetic acid
1148-11-4 1609-86-5, tert-Butyl isocyanate 3182-95-4,

L-Phenylalaninol

3391-99-9 3392-08-3 4530-20-5 15761-39-4 21691-41-8,
N-Benzyloxycarbonyl-N-methyl-L-alanine 26049-94-5 62965-10-0
68223-03-0, N-Benzyloxycarbonyl-N-methyl-D-alanine 112898-22-3

RL: RCT (Reactant)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 111060-52-7P 111060-64-1P 111138-83-1P 127927-43-9P 128018-43-9P
128018-44-0P 143224-67-3P 143224-89-9P 143224-90-2P 143224-91-3P
143225-04-1P 168056-71-1P 168056-72-2P 168056-73-3P 168056-74-4P
168056-75-5P 168056-76-6P 168056-77-7P 168056-78-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 37205-61-1, Protease inhibitor

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL
(Biological study)

(retroviral; prepn. of phenylstatine derivs. as retroviral protease
inhibitors)

L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1994:153741 CAPLUS

DN 120:153741

TI Use of antiretroviral drugs for treatment of motor neuron diseases

IN Westarp, Martin Egon; Kornhuber, Hans Helmut

PA Germany

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-70

ICS A61K031-55; A61K031-505; A61K031-66; A61K031-445; A61K031-47

ICI A61K031-70, A61K031-55, A61K031-505, A61K031-66, A61K031-445, A61K031-47

CC 1-11 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 4307883	A1	19930923	DE 1993-4307883	19930312
PRAI	DE 1992-4207863		19920312		
AB	Nucleoside analogs and other antiretroviral agents are useful for treatment of diseases of motor neurons, such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and progressive bulbar paralysis. Thus, administration of zidovudine (500 mg/day orally for				
2-10	mo) to ALS patients reversed the elevation in serum creatine kinase level characteristic of ALS in 8 of 10 patients.				
ST	motor nerve disease treatment virucide; amyotrophic lateral sclerosis retrovirus drug; zidovudine nerve disease				
IT	Virucides and Virustats				
	(for retroviruses, motor neuron disease treatment with)				
IT	Ribonucleic acids, viral				
	RL: BIOL (Biological study)				
	(of retrovirus, antisense, motor neuron disease treatment with)				
IT	Virus, animal				
	(Maedi-Visna, antisense RNA of, motor neuron disease treatment with)				
IT	Paralysis				
	(bulbar, progressive, treatment of, with retrovirus inhibitors)				

IT Nervous system
 (disease, amyotrophic lateral sclerosis, treatment of, with retrovirus inhibitors)

IT Nervous system
 (disease, spinal muscular atrophy, treatment of, with retrovirus inhibitors)

IT Virus, animal
 (foamy, antisense RNA of, motor neuron disease treatment with)

IT Nerve, disease
 (motor, treatment of, with retrovirus inhibitors)

IT Virus, animal
 (retro-, inhibitors of, motor neuron disease treatment with)

IT Proteins, specific or class
 RL: BIOL (Biological study)
 (trichosanthins, motor neuron disease treatment with)

IT 9068-38-6, Reverse transcriptase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, motor neuron disease treatment with)

IT 50-48-6, Amitriptyline 52-67-5 53-43-0, Dehydroepiandrosterone
 62-46-4, 1,2-Dithiolane-3-pentanoic acid 70-00-8, Trifluorothymidine
 360-97-4, 5-Aminoimidazole-4-carboxamide 548-04-9, Hypericin
 616-91-1,
 N-Acetylcysteine 1077-28-7 3056-17-5 4317-14-0, Amitriptyline oxide
 4408-78-0, Phosphonoacetic acid 4428-95-9, Foscarnet 6493-05-6,
 Pentoxifylline 6736-58-9, 3-Deazaadenosine 7481-89-2, Dideoxycytidine
 9042-14-2, Dextran sulfate 16561-29-8 **19130-96-2**,
 Deoxynojirimycin 19750-45-9 30195-30-3 30516-87-1, Azidothymidine
 36791-04-5, Ribavirin 58821-98-0, 12-Deoxyphorbol 13-phenylacetate
 59372-48-4, Ammonium antimony tungsten oxide 60857-08-1,
 12-Deoxyphorbol
 13-acetate 69655-05-6, Dideoxyinosine **72599-27-0**
 112190-24-6, U-75875 123027-56-5 126347-69-1, R82913 127779-20-8
 127875-60-9, A-80915A 129618-40-2, Nevirapine 132774-45-9
 132774-46-0 134458-76-7 **134678-17-4** 134680-32-3
 136816-67-6 136816-72-3, U 85961 136816-75-6, U 87201 136816-75-6D,
 U 87201, esters 136816-76-7, U 88204 136816-84-7, U 88352
 136816-85-8, U 88353 136891-12-8 137622-85-6 140459-12-7,
 Fluorothymidine 143616-58-4 147362-54-7, R 18893 148465-15-0, L697
 153374-32-4 153411-01-9 153550-37-9, L 661
 RL: BIOL (Biological study)
 (motor neuron disease treatment with)

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1 32 S E1-E3

L2 10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3 31704 S E3

L4 4491 S HBV

L5 751 S L1

L6 1070 S L2

IT Nervous system
 (disease, amyotrophic lateral sclerosis, treatment of, with retrovirus inhibitors)

IT Nervous system
 (disease, spinal muscular atrophy, treatment of, with retrovirus inhibitors)

IT Virus, animal
 (foamy, antisense RNA of, motor neuron disease treatment with)

IT Nerve, disease
 (motor, treatment of, with retrovirus inhibitors)

IT Virus, animal
 (retro-, inhibitors of, motor neuron disease treatment with)

IT Proteins, specific or class
 RL: BIOL (Biological study)
 (trichosanthins, motor neuron disease treatment with)

IT 9068-38-6, Reverse transcriptase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, motor neuron disease treatment with)

IT 50-48-6, Amitriptyline 52-67-5 53-43-0, Dehydroepiandrosterone
 62-46-4, 1,2-Dithiolane-3-pentanoic acid 70-00-8, Trifluorothymidine
 360-97-4, 5-Aminoimidazole-4-carboxamide 548-04-9, Hypericin
 616-91-1,
 N-Acetylcysteine 1077-28-7 3056-17-5 4317-14-0, Amitriptyline oxide
 4408-78-0, Phosphonoacetic acid 4428-95-9, Foscarnet 6493-05-6,
 Pentoxifylline 6736-58-9, 3-Deazaadenosine 7481-89-2, Dideoxycytidine
 9042-14-2, Dextran sulfate 16561-29-8 **19130-96-2**,
 Deoxynojirimycin 19750-45-9 30195-30-3 30516-87-1, Azidothymidine
 36791-04-5, Ribavirin 58821-98-0, 12-Deoxyphorbol 13-phenylacetate
 59372-48-4, Ammonium antimony tungsten oxide 60857-08-1,
 12-Deoxyphorbol
 13-acetate 69655-05-6, Dideoxyinosine **72599-27-0**
 112190-24-6, U-75875 123027-56-5 126347-69-1, R82913 127779-20-8
 127875-60-9, A-80915A 129618-40-2, Nevirapine 132774-45-9
 132774-46-0 134458-76-7 **134678-17-4** 134680-32-3
 136816-67-6 136816-72-3, U 85961 136816-75-6, U 87201 136816-75-6D,
 U 87201, esters 136816-76-7, U 88204 136816-84-7, U 88352
 136816-85-8, U 88353 136891-12-8 137622-85-6 140459-12-7,
 Fluorothymidine 143616-58-4 147362-54-7, R 18893 148465-15-0, L697
 153374-32-4 153411-01-9 153550-37-9, L 661
 RL: BIOL (Biological study)
 (motor neuron disease treatment with)

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1 32 S E1-E3

L2 10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3 31704 S E3

L4 4491 S HBV

L5 751 S L1

L6 1070 S L2

L7 16 S L5 AND L6

=> s 16 and 13

L8 271 L6 AND L3

=> s 18 and 14

L9 176 L8 AND L4

=> s 19 and antiviral

32353 ANTIVIRAL

L10 160 L9 AND ANTIVIRAL

=> d 110 110-160

L10 ANSWER 110 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1999:249268 CAPLUS

DN 131:82389

TI **Antiviral** treatment for human immunodeficiency virus patients co-infected with **hepatitis** B virus: combined effect for both infections, an obtainable goal?

AU Wolters, Leonieke M. M.; Niesters, Hubert G. M.; de Man, Robert A.; Schalm, Solko W.

CS Department of Hepatogastroenterology, University Hospital Rotterdam, Rotterdam, 3000 CA, Neth.

SO Antiviral Res. (1999), 42(1), 71-76
CODEN: ARSRDR; ISSN: 0166-3542

PB Elsevier Science B.V.

DT Journal; General Review

LA English

RE.CNT 19

RE

(3) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS

(5) Boucher, C; Antimicrob Agents Chemother 1993, V37, P2231 CAPLUS

(8) Eron, J; New Engl J Med 1995, V333, P1662 CAPLUS

(11) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS

(15) Ling, R; Hepatology 1996, V24, P711 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 111 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1999:209794 CAPLUS

DN 130:276292

TI Efficacy of lamivudine in patients with **hepatitis** B virus precore mutant infection before and after liver transplantation

AU Ben-Ari, Ziv; Zemel, Romy; Kazetsker, Anna; Fraser, Gerald; Tur-Kaspa, Ran

CS Liver Institute, Department of Medicine D, Tel Aviv University, Tel Aviv-Jaffa, Israel

SO Am. J. Gastroenterol. (1999), 94(3), 663-667
CODEN: AJGAAR; ISSN: 0002-9270

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 21

RE

(2) Bain, V; Transplantation 1996, V62, P1456 CAPLUS

(4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS

(7) Carman, W; Gastroenterology 1992, V102, P711 CAPLUS

(9) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS

L7 16 S L5 AND L6

=> s 16 and 13

L8 271 L6 AND L3

=> s 18 and 14

L9 176 L8 AND L4

=> s 19 and antiviral

32353 ANTIVIRAL

L10 160 L9 AND ANTIVIRAL

=> d 110 110-160

L10 ANSWER 110 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1999:249268 CAPLUS

DN 131:82389

TI **Antiviral** treatment for human immunodeficiency virus patients co-infected with **hepatitis** B virus: combined effect for both infections, an obtainable goal?

AU Wolters, Leonieke M. M.; Niesters, Hubert G. M.; de Man, Robert A.; Schalm, Solko W.

CS Department of Hepatogastroenterology, University Hospital Rotterdam, Rotterdam, 3000 CA, Neth.

SO Antiviral Res. (1999), 42(1), 71-76
CODEN: ARSRDR; ISSN: 0166-3542

PB Elsevier Science B.V.

DT Journal; General Review

LA English

RE.CNT 19

RE

(3) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS

(5) Boucher, C; Antimicrob Agents Chemother 1993, V37, P2231 CAPLUS

(8) Eron, J; New Engl J Med 1995, V333, P1662 CAPLUS

(11) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS

(15) Ling, R; Hepatology 1996, V24, P711 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 111 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1999:209794 CAPLUS

DN 130:276292

TI Efficacy of lamivudine in patients with **hepatitis** B virus precore mutant infection before and after liver transplantation

AU Ben-Ari, Ziv; Zemel, Romy; Kazetsker, Anna; Fraser, Gerald; Tur-Kaspa, Ran

CS Liver Institute, Department of Medicine D, Tel Aviv University, Tel Aviv-Jaffa, Israel

SO Am. J. Gastroenterol. (1999), 94(3), 663-667
CODEN: AJGAAR; ISSN: 0002-9270

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 21

RE

(2) Bain, V; Transplantation 1996, V62, P1456 CAPLUS

(4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS

(7) Carman, W; Gastroenterology 1992, V102, P711 CAPLUS

(9) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS

(15) Laskus, T; J Hepatol 1994, V20, P837 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 112 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:198028 CAPLUS
DN 131:39256
TI YMDD motif in **hepatitis** B virus DNA polymerase influences on
replication and lamivudine resistance: a study by in vitro full-length
viral DNA transfection
AU Ono-Nita, Suzane Kioko; Kato, Naoya; Shiratori, Yasushi; Masaki, Tsutomu;
Lan, Keng-Hsin; Carrilho, Flair Jose; Omata, Masao
CS Second Department of Internal Medicine, Faculty of Medicine, University
of
Tokyo, Tokyo, 113, Japan
SO Hepatology (Philadelphia) (1999), 29(3), 939-945
CODEN: HPTLD9; ISSN: 0270-9139
PB W. B. Saunders Co.
DT Journal
LA English
RE.CNT 43
RE
(2) Back, N; EMBO J 1996, V15, P4040 CAPLUS
(3) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
(4) Balter, M; Science 1996, V274, P1988 CAPLUS
(6) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS
(7) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 113 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:198025 CAPLUS
DN 131:39255
TI Efficacy of lamivudine in patients with **hepatitis** B e
antigen-negative/**hepatitis** B virus DNA-positive (precore mutant)
chronic **hepatitis** B
AU Tassopoulos, Nicolaos C.; Volpes, Riccardo; Pastore, Giuseppe; Heathcote,
Jenny; Buti, Maria; Goldin, Robert D.; Hawley, Sasha; Barber, Judy;
Condreay, Lynn; Gray, D. Fraser
CS The Lamivudine Precore Mutant Study Group, Western Attica General
Hospital, Athens, 123 51, Greece
SO Hepatology (Philadelphia) (1999), 29(3), 889-896
CODEN: HPTLD9; ISSN: 0270-9139
PB W. B. Saunders Co.
DT Journal
LA English
RE.CNT 41
RE
(2) Allen, M; Hepatology 1998, V27, P1670 CAPLUS
(9) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
(10) Dusheiko, G; Pharmacol Ther 1995, V65, P47 CAPLUS
(13) Fischer, K; Antimicrob Agents Chemother 1996, V40, P1957 CAPLUS
(22) Lai, C; Hepatology 1997, V25, P241 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 114 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:194745 CAPLUS
DN 131:39251
TI **Hepatitis** B virus variants with lamivudine-related mutations in
the DNA polymerase and the 'a' epitope of the surface antigen are

(15) Laskus, T; J Hepatol 1994, V20, P837 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 112 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:198028 CAPLUS
DN 131:39256
TI YMDD motif in **hepatitis** B virus DNA polymerase influences on
replication and lamivudine resistance: a study by in vitro full-length
viral DNA transfection
AU Ono-Nita, Suzane Kioko; Kato, Naoya; Shiratori, Yasushi; Masaki, Tsutomu;
Lan, Keng-Hsin; Carrilho, Flair Jose; Omata, Masao
CS Second Department of Internal Medicine, Faculty of Medicine, University
of
Tokyo, Tokyo, 113, Japan
SO Hepatology (Philadelphia) (1999), 29(3), 939-945
CODEN: HPTLD9; ISSN: 0270-9139
PB W. B. Saunders Co.
DT Journal
LA English
RE.CNT 43
RE
(2) Back, N; EMBO J 1996, V15, P4040 CAPLUS
(3) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
(4) Balter, M; Science 1996, V274, P1988 CAPLUS
(6) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS
(7) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 113 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:198025 CAPLUS
DN 131:39255
TI Efficacy of lamivudine in patients with **hepatitis** B e
antigen-negative/**hepatitis** B virus DNA-positive (precore mutant)
chronic **hepatitis** B
AU Tassopoulos, Nicolaos C.; Volpes, Riccardo; Pastore, Giuseppe; Heathcote,
Jenny; Buti, Maria; Goldin, Robert D.; Hawley, Sasha; Barber, Judy;
Condreay, Lynn; Gray, D. Fraser
CS The Lamivudine Precore Mutant Study Group, Western Attica General
Hospital, Athens, 123 51, Greece
SO Hepatology (Philadelphia) (1999), 29(3), 889-896
CODEN: HPTLD9; ISSN: 0270-9139
PB W. B. Saunders Co.
DT Journal
LA English
RE.CNT 41
RE
(2) Allen, M; Hepatology 1998, V27, P1670 CAPLUS
(9) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
(10) Dusheiko, G; Pharmacol Ther 1995, V65, P47 CAPLUS
(13) Fischer, K; Antimicrob Agents Chemother 1996, V40, P1957 CAPLUS
(22) Lai, C; Hepatology 1997, V25, P241 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 114 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:194745 CAPLUS
DN 131:39251
TI **Hepatitis** B virus variants with lamivudine-related mutations in
the DNA polymerase and the 'a' epitope of the surface antigen are

sensitive to ganciclovir
AU Jin Oon, Chong; Ning Chen, Wei; Lim, Nichole; Koh, Shiuan; Keow Lim, Gek;
Lin Leong, Ai; San Tan, Gek
CS Department of Clinical Research, Ransome Research Laboratory, Singapore
General Hospital, Singapore
SO Antiviral Res. (1999), 41(3), 113-118
CODEN: ARSRDR; ISSN: 0166-3542
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 10
RE

- (2) Carman, W; Hepatology 1997, V26, P1658 CAPLUS
(3) Carman, W; Lancet 1995, V345, P1406 CAPLUS
(4) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
(5) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS
(6) Lai, C; Hepatology 1997, V25, P241 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 115 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:188556 CAPLUS
DN 131:238
TI Functional analysis of mutations conferring lamivudine resistance on
hepatitis B virus
AU Ling, R.; Harrison, T. J.
CS Department of Medicine, Royal Free and University College Medical School,
University College London, London, NW3 2PF, UK
SO J. Gen. Virol. (1999), 80(3), 601-606
CODEN: JGVIAY; ISSN: 0022-1317
PB Society for General Microbiology
DT Journal
LA English
RE.CNT 30
RE

- (1) Allen, M; Hepatology 1998, V27, P1670 CAPLUS
(2) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
(4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS
(6) Buti, M; Journal of Hepatology 1998, V28, P510 CAPLUS
(7) Chayama, K; Hepatology 1998, V27, P1711 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 116 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:185603 CAPLUS
DN 130:291211
TI Good results of lamivudine in **hepatitis** B surface
antigen-positive patients with active viral replication before liver
transplantation
AU Gugenheim, J.; Baldini, E.; Ouzan, D.; Sowka, P.; Mouiel, J.
CS Service de Chirurgie Digestive, Universite de Sophia Antipolis, Nice, Fr.
SO Transplant. Proc. (1999), 31(1/2), 554-555
CODEN: TRPPA8; ISSN: 0041-1345
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 8
RE

- (1) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
(2) Benhamou, Y; Lancet 1995, V345, P396 MEDLINE

sensitive to ganciclovir
AU Jin Oon, Chong; Ning Chen, Wei; Lim, Nichole; Koh, Shiuan; Keow Lim, Gek;
Lin Leong, Ai; San Tan, Gek
CS Department of Clinical Research, Ransome Research Laboratory, Singapore
General Hospital, Singapore
SO Antiviral Res. (1999), 41(3), 113-118
CODEN: ARSRDR; ISSN: 0166-3542
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 10
RE

- (2) Carman, W; Hepatology 1997, V26, P1658 CAPLUS
 - (3) Carman, W; Lancet 1995, V345, P1406 CAPLUS
 - (4) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
 - (5) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS
 - (6) Lai, C; Hepatology 1997, V25, P241 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 115 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:188556 CAPLUS
DN 131:238
TI Functional analysis of mutations conferring lamivudine resistance on
hepatitis B virus
AU Ling, R.; Harrison, T. J.
CS Department of Medicine, Royal Free and University College Medical School,
University College London, London, NW3 2PF, UK
SO J. Gen. Virol. (1999), 80(3), 601-606
CODEN: JGVIAY; ISSN: 0022-1317
PB Society for General Microbiology
DT Journal
LA English
RE.CNT 30
RE

- (1) Allen, M; Hepatology 1998, V27, P1670 CAPLUS
 - (2) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
 - (4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS
 - (6) Buti, M; Journal of Hepatology 1998, V28, P510 CAPLUS
 - (7) Chayama, K; Hepatology 1998, V27, P1711 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 116 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:185603 CAPLUS
DN 130:291211
TI Good results of lamivudine in **hepatitis** B surface
antigen-positive patients with active viral replication before liver
transplantation
AU Gugenheim, J.; Baldini, E.; Ouzan, D.; Sowka, P.; Mouiel, J.
CS Service de Chirurgie Digestive, Universite de Sophia Antipolis, Nice, Fr.
SO Transplant. Proc. (1999), 31(1/2), 554-555
CODEN: TRPPA8; ISSN: 0041-1345
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 8
RE

- (1) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
- (2) Benhamou, Y; Lancet 1995, V345, P396 MEDLINE

- (3) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
(5) Gugenheim, J; Trans Proc 1997, V29, P517 MEDLINE
(6) Marcellin, P; Hepatology 1994, V19, P6 MEDLINE

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 117 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:167057 CAPLUS
DN 130:252593
TI The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir. Part I. Synthesis and in vitro anti-**hepatitis** B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir
AU Perigaud, Christian; Gosselin, Gilles; Girardet, Jean-Luc; Korba, Brent E.; Imbach, Jean-Louis
CS U.M.R. C.N.R.S. 5625, Laboratoire de Chimie Bioorganique, Universite Montpellier II, Montpellier, 34095, Fr.
SO Antiviral Res. (1999), 40(3), 167-178
CODEN: ARSRDR; ISSN: 0166-3542
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 40
RE

- (2) Alexander, P; Collect Czech Chem Commun 1994, V59, P2127 CAPLUS
(4) Aoki-Sei, S; J Infect Dis 1991, V164, P843 CAPLUS
(5) Arner, E; Pharm Ther 1995, V67, P155 CAPLUS
(6) Belen'Kii, M; Antiviral Res 1994, V25, P1 CAPLUS
(8) Chou, T; Adv Enzyme Regul 1984, V22, P27 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 118 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:117751 CAPLUS
DN 131:220
TI The **hepatitis** B virus-trimera mouse: a model for human **HBV** infection and evaluation of anti-**HBV** therapeutic agents
AU Ilan, Ehud; Burakova, Tatjana; Dagan, Shlomo; Nussbaum, Ofer; Lubin, Ido; Eren, Rachel; Ben-Moshe, Ofer; Arazi, Joseph; Berr, Shoshana; Neville, Lewis; Yuen, Leonard; Mansour, Tarek S.; Gillard, John; Eid, Ahamed; Jurim, Oded; Shouval, Daniel; Reisner, Yair; Galun, Eithan
CS XTL Biopharmaceuticals Ltd, Rehovot, 76100, Israel
SO Hepatology (Philadelphia) (1999), 29(2), 553-562
CODEN: HPTLD9; ISSN: 0270-9139
PB W. B. Saunders Co.
DT Journal
LA English
RE.CNT 36
RE

- (2) Cardillo, F; J Immunol Methods 1995, V188, P43 CAPLUS
(3) Caselmann, W; Antiviral Res 1994, V24, P121 CAPLUS
(4) Chisari, F; Cell 1989, V59, P1145 CAPLUS
(5) Chisari, F; J Virol 1986, V60, P880 CAPLUS
(6) Chomczynski, P; Biotechniques 1997, V22, P550 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 119 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:109354 CAPLUS
DN 130:246369
TI Lamivudine therapy for chemotherapy-induced reactivation of

- (3) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
(5) Gugenheim, J; Trans Proc 1997, V29, P517 MEDLINE
(6) Marcellin, P; Hepatology 1994, V19, P6 MEDLINE

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 117 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:167057 CAPLUS
DN 130:252593
TI The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir. Part I. Synthesis and in vitro anti-**hepatitis** B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir
AU Perigaud, Christian; Gosselin, Gilles; Girardet, Jean-Luc; Korba, Brent E.; Imbach, Jean-Louis
CS U.M.R. C.N.R.S. 5625, Laboratoire de Chimie Bioorganique, Universite Montpellier II, Montpellier, 34095, Fr.
SO Antiviral Res. (1999), 40(3), 167-178
CODEN: ARSRDR; ISSN: 0166-3542
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 40
RE

- (2) Alexander, P; Collect Czech Chem Commun 1994, V59, P2127 CAPLUS
(4) Aoki-Sei, S; J Infect Dis 1991, V164, P843 CAPLUS
(5) Arner, E; Pharm Ther 1995, V67, P155 CAPLUS
(6) Belen'Kii, M; Antiviral Res 1994, V25, P1 CAPLUS
(8) Chou, T; Adv Enzyme Regul 1984, V22, P27 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 118 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:117751 CAPLUS
DN 131:220
TI The **hepatitis** B virus-trimera mouse: a model for human **HBV** infection and evaluation of anti-**HBV** therapeutic agents
AU Ilan, Ehud; Burakova, Tatjana; Dagan, Shlomo; Nussbaum, Ofer; Lubin, Ido; Eren, Rachel; Ben-Moshe, Ofer; Arazi, Joseph; Berr, Shoshana; Neville, Lewis; Yuen, Leonard; Mansour, Tarek S.; Gillard, John; Eid, Ahamed; Jurim, Oded; Shouval, Daniel; Reisner, Yair; Galun, Eithan
CS XTL Biopharmaceuticals Ltd, Rehovot, 76100, Israel
SO Hepatology (Philadelphia) (1999), 29(2), 553-562
CODEN: HPTLD9; ISSN: 0270-9139
PB W. B. Saunders Co.
DT Journal
LA English
RE.CNT 36
RE

- (2) Cardillo, F; J Immunol Methods 1995, V188, P43 CAPLUS
(3) Caselmann, W; Antiviral Res 1994, V24, P121 CAPLUS
(4) Chisari, F; Cell 1989, V59, P1145 CAPLUS
(5) Chisari, F; J Virol 1986, V60, P880 CAPLUS
(6) Chomczynski, P; Biotechniques 1997, V22, P550 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 119 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1999:109354 CAPLUS
DN 130:246369
TI Lamivudine therapy for chemotherapy-induced reactivation of

hepatitis B virus infection
 AU Ahmed, Aijaz; Keefe, Emmet B.
 CS Division of Gastroenterology, Department of Medicine, Stanford University
 School of Medicine, Stanford, CA, USA
 SO Am. J. Gastroenterol. (1999), 94(1), 249-251
 CODEN: AJGAAR; ISSN: 0002-9270
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 40
 RE
 (3) Benhamou, Y; Lancet 1995, V345, P396 MEDLINE
 (4) Bird, G; Q J Med 1989, V73, P895 MEDLINE
 (5) Dienstag, J; N Eng J Med 1995, V333, P1657 CAPLUS
 (6) Flowers, M; Ann Intern Med 1990, V112, P381 MEDLINE
 (32) Rostaing, L; Transplantation 1997, V64, P1624 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 120 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1999:37155 CAPLUS
 DN 130:276259
 TI Transient selection of a **hepatitis B** virus polymerase gene
 mutant associated with a decreased replication capacity and famciclovir
 resistance
 AU Pichoud, Christian; Seigneres, Beatrice; Wang, Zhirui; Trepo, Christian;
 Zoulim, Fabien
 CS INSERM Unit 271, Lyon, 69003, Fr.
 SO Hepatology (Philadelphia) (1999), 29(1), 230-237
 CODEN: HPTLD9; ISSN: 0270-9139
 PB W. B. Saunders Co.
 DT Journal
 LA English
 RE.CNT 40
 RE
 (1) Arts, E; Antimicrob Agents Chemother 1996, V40, P527 CAPLUS
 (6) Dannaoui, E; Antivir Chem Chemother 1997, V8, P38 CAPLUS
 (7) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
 (9) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS
 (11) Horwich, A; J Virol 1990, V64, P642 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 121 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1999:12153 CAPLUS
 DN 130:204703
 TI Lamivudine treatment for acute **hepatitis B** after liver
 transplantation
 AU Andreone, Pietro; Caraceni, Paolo; Grazi, Gian Luca; Belli, Luca;
 Milandri, Gian Luigi; Ercolani, Giorgio; Jovine, Elio; D'Errico, Antonia;
 Monte, Pier Roberto Dal; Ideo, Gaetano; Forti, Domenico; Mazziotti,
 Alighieri; Cavallari, Antonino; Bernardi, Mauro
 CS Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia,
 University of Bologna, Bologna, Italy
 SO J. Hepatol. (1998), 29(6), 985-989
 CODEN: JOHEEC; ISSN: 0168-8278
 PB Munksgaard International Publishers Ltd.
 DT Journal
 LA English
 RE.CNT 12

hepatitis B virus infection
 AU Ahmed, Aijaz; Keefte, Emmet B.
 CS Division of Gastroenterology, Department of Medicine, Stanford University
 School of Medicine, Stanford, CA, USA
 SO Am. J. Gastroenterol. (1999), 94(1), 249-251
 CODEN: AJGAAR; ISSN: 0002-9270
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 40
 RE
 (3) Benhamou, Y; Lancet 1995, V345, P396 MEDLINE
 (4) Bird, G; Q J Med 1989, V73, P895 MEDLINE
 (5) Dienstag, J; N Eng J Med 1995, V333, P1657 CAPLUS
 (6) Flowers, M; Ann Intern Med 1990, V112, P381 MEDLINE
 (32) Rostaing, L; Transplantation 1997, V64, P1624 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 120 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1999:37155 CAPLUS
 DN 130:276259
 TI Transient selection of a **hepatitis B** virus polymerase gene
 mutant associated with a decreased replication capacity and famciclovir
 resistance
 AU Pichoud, Christian; Seignerres, Beatrice; Wang, Zhirui; Treppe, Christian;
 Zoulim, Fabien
 CS INSERM Unit 271, Lyon, 69003, Fr.
 SO Hepatology (Philadelphia) (1999), 29(1), 230-237
 CODEN: HPTLD9; ISSN: 0270-9139
 PB W. B. Saunders Co.
 DT Journal
 LA English
 RE.CNT 40
 RE
 (1) Arts, E; Antimicrob Agents Chemother 1996, V40, P527 CAPLUS
 (6) Dannaoui, E; Antivir Chem Chemother 1997, V8, P38 CAPLUS
 (7) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
 (9) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS
 (11) Horwich, A; J Virol 1990, V64, P642 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 121 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1999:12153 CAPLUS
 DN 130:204703
 TI Lamivudine treatment for acute **hepatitis B** after liver
 transplantation
 AU Andreone, Pietro; Caraceni, Paolo; Grazi, Gian Luca; Belli, Luca;
 Milandri, Gian Luigi; Ercolani, Giorgio; Jovine, Elio; D'Errico, Antonia;
 Monte, Pier Roberto Dal; Ideo, Gaetano; Forti, Domenico; Mazziotti,
 Alighieri; Cavallari, Antonino; Bernardi, Mauro
 CS Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia,
 University of Bologna, Bologna, Italy
 SO J. Hepatol. (1998), 29(6), 985-989
 CODEN: JOHEEC; ISSN: 0168-8278
 PB Munksgaard International Publishers Ltd.
 DT Journal
 LA English
 RE.CNT 12

RE

- (1) Al Faraidy, K; Transplantation 1997, V64, P926 MEDLINE
- (3) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
- (4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS
- (7) Nevens, F; Gastroenterology 1997, V113, P1258 CAPLUS
- (12) Tipples, G; Hepatology 1996, V24, P714 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 122 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:810358 CAPLUS

DN 130:217639

TI Mutations in **hepatitis** B DNA polymerase associated with
resistance to lamivudine do not confer resistance to adefovir in vitro

AU Xiong, Xiaofeng; Flores, Carmina; Yang, Huiling; Toole, John J.; Gibbs,
Graig S.

CS Gilead Sciences, Foster City, CA, 94404, USA

SO Hepatology (Philadelphia) (1998), 28(6), 1669-1673
CODEN: HPTLD9; ISSN: 0270-9139

PB W. B. Saunders Co.

DT Journal

LA English

RE.CNT 39

RE

- (6) Cleland, W; Methods in Enzymology 1979, V63, P103 CAPLUS
- (7) de Clercq, E; Antiviral Res 1987, V8, P261 CAPLUS
- (8) de Clercq, E; Nature 1986, V323, P464 CAPLUS
- (9) de Clercq, E; Nucleosides Nucleotides 1994, V13, P1271 CAPLUS
- (10) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 123 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:719749 CAPLUS

DN 130:75800

TI Pharmacodynamics of (-)-.beta.-2',3'-dideoxy-3'-thiacytidine in
chronically virus-infected woodchucks compared to its pharmacodynamics in
humans

AU Hurwitz, Selwyn J.; Tennant, Bud C.; Korba, Brent E.; Gerin, John L.;
Schinazi, Raymond F.

CS Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory
University School of Medicine and Veterans Affairs Medical Center,
Decatur, GA, 300337, USA

SO Antimicrob. Agents Chemother. (1998), 42(11), 2804-2809
CODEN: AMACCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

RE.CNT 27

RE

- (3) Cammack, N; Biochem Pharmacol 1992, V43, P2059 CAPLUS
- (4) Chang, C; J Biol Chem 1992, V267, P13938 CAPLUS
- (5) Fourel, I; J Virol 1994, V68, P8321 CAPLUS
- (11) Korba, B; Hepatology 1996, V23, P958 CAPLUS
- (15) Moore, K; Clin Pharmacol Ther 1996, V59, P550 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 124 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:681693 CAPLUS

DN 130:75790

RE

- (1) Al Faraidy, K; Transplantation 1997, V64, P926 MEDLINE
- (3) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
- (4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS
- (7) Nevens, F; Gastroenterology 1997, V113, P1258 CAPLUS
- (12) Tipples, G; Hepatology 1996, V24, P714 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 122 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:810358 CAPLUS

DN 130:217639

TI Mutations in **hepatitis** B DNA polymerase associated with
resistance to lamivudine do not confer resistance to adefovir in vitro

AU Xiong, Xiaofeng; Flores, Carmina; Yang, Huiling; Toole, John J.; Gibbs,
Graig S.

CS Gilead Sciences, Foster City, CA, 94404, USA

SO Hepatology (Philadelphia) (1998), 28(6), 1669-1673
CODEN: HPTLD9; ISSN: 0270-9139

PB W. B. Saunders Co.

DT Journal

LA English

RE.CNT 39

RE

- (6) Cleland, W; Methods in Enzymology 1979, V63, P103 CAPLUS
- (7) de Clercq, E; Antiviral Res 1987, V8, P261 CAPLUS
- (8) de Clercq, E; Nature 1986, V323, P464 CAPLUS
- (9) de Clercq, E; Nucleosides Nucleotides 1994, V13, P1271 CAPLUS
- (10) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 123 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:719749 CAPLUS

DN 130:75800

TI Pharmacodynamics of (-)-.beta.-2',3'-dideoxy-3'-thiacytidine in
chronically virus-infected woodchucks compared to its pharmacodynamics in
humans

AU Hurwitz, Selwyn J.; Tennant, Bud C.; Korba, Brent E.; Gerin, John L.;
Schinazi, Raymond F.

CS Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory
University School of Medicine and Veterans Affairs Medical Center,
Decatur, GA, 300337, USA

SO Antimicrob. Agents Chemother. (1998), 42(11), 2804-2809
CODEN: AMACQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

RE.CNT 27

RE

- (3) Cammack, N; Biochem Pharmacol 1992, V43, P2059 CAPLUS
- (4) Chang, C; J Biol Chem 1992, V267, P13938 CAPLUS
- (5) Fourel, I; J Virol 1994, V68, P8321 CAPLUS
- (11) Korba, B; Hepatology 1996, V23, P958 CAPLUS
- (15) Moore, K; Clin Pharmacol Ther 1996, V59, P550 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 124 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:681693 CAPLUS

DN 130:75790

TI Transient emergence of **hepatitis** B variants in a patient with
chronic **hepatitis** B resistant to lamivudine
AU Buti, Maria; Jardi, Rosendo; Cotrina, Montserrat; Rodriguez-Frias,
Francisco; Esteban, Rafael; Guardia, Jaime
CS Liver Unit, Hospital General Universitario Valle Hebron, Barcelona,
08035,
Spain
SO J. Hepatol. (1998), 28(3), 510-513
CODEN: JOHEEC; ISSN: 0168-8278
PB Munksgaard International Publishers Ltd.
DT Journal
LA English
RE.CNT 11
RE

- (1) Bartholomew, M; Lancet 1997, V349, P20 MEDLINE
 - (4) Grellier, L; Lancet 1996, V348, P1212 MEDLINE
 - (6) Lai, C; Hepatology 1997, V25, P241 CAPLUS
 - (7) Ling, R; Hepatology 1996, V24, P711 CAPLUS
 - (11) Tipples, G; Hepatology 1996, V24, P714 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 125 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1998:681420 CAPLUS
DN 130:75788
TI Clinical impact of lamivudine resistance in chronic **hepatitis** B
AU Honkoop, Pieter; De Man, Robert A.; Niesters, Hubert G. M.; Schalm, Solko
W.
CS Department of Hepatogastroenterology, Erasmus University Hospital,
Rotterdam, Neth.
SO J. Hepatol. (1998), 29(3), 510-511
CODEN: JOHEEC; ISSN: 0168-8278
PB Munksgaard International Publishers Ltd.
DT Journal
LA English
RE.CNT 5
RE

- (1) Bartholomew, M; Lancet 1997, V349, P20 MEDLINE
- (2) de Man, R; To be published in J Hepatol 1998
- (3) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS
- (4) Leung, N; Hepatology 1997, V26(Suppl), P357
- (5) Niesters, H; J Infect Dis 1998, V177, P1382 CAPLUS

L10 ANSWER 126 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1998:680662 CAPLUS
DN 130:75781
TI Combination alpha-interferon and lamivudine therapy for
alpha-interferon-resistant chronic **hepatitis** B infection:
results of a pilot study
AU Mutimer, David; Naoumov, Nicolai; Honkoop, Pieter; Marinos, George;
Ahmed,
Monz; de Man, Robert; McPhillips, Penny; Johnson, Mark; Williams, Roger;
Elias, Elwyn; Schalm, Solko
CS Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Birmingham, B15
2TH, UK
SO J. Hepatol. (1998), 28(6), 923-929
CODEN: JOHEEC; ISSN: 0168-8278
PB Munksgaard International Publishers Ltd.
DT Journal

TI Transient emergence of **hepatitis** B variants in a patient with
chronic **hepatitis** B resistant to lamivudine
AU Buti, Maria; Jardi, Rosendo; Cotrina, Montserrat; Rodriguez-Frias,
Francisco; Esteban, Rafael; Guardia, Jaime
CS Liver Unit, Hospital General Universitario Valle Hebron, Barcelona,
08035,
Spain
SO J. Hepatol. (1998), 28(3), 510-513
CODEN: JOHEEC; ISSN: 0168-8278
PB Munksgaard International Publishers Ltd.
DT Journal
LA English
RE.CNT 11
RE

- (1) Bartholomew, M; Lancet 1997, V349, P20 MEDLINE
 - (4) Grellier, L; Lancet 1996, V348, P1212 MEDLINE
 - (6) Lai, C; Hepatology 1997, V25, P241 CAPLUS
 - (7) Ling, R; Hepatology 1996, V24, P711 CAPLUS
 - (11) Tipples, G; Hepatology 1996, V24, P714 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 125 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1998:681420 CAPLUS
DN 130:75788
TI Clinical impact of lamivudine resistance in chronic **hepatitis** B
AU Honkoop, Pieter; De Man, Robert A.; Niesters, Hubert G. M.; Schalm, Solko
W.
CS Department of Hepatogastroenterology, Erasmus University Hospital,
Rotterdam, Neth.
SO J. Hepatol. (1998), 29(3), 510-511
CODEN: JOHEEC; ISSN: 0168-8278
PB Munksgaard International Publishers Ltd.
DT Journal
LA English
RE.CNT 5
RE

- (1) Bartholomew, M; Lancet 1997, V349, P20 MEDLINE
- (2) de Man, R; To be published in J Hepatol 1998
- (3) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS
- (4) Leung, N; Hepatology 1997, V26(Suppl), P357
- (5) Niesters, H; J Infect Dis 1998, V177, P1382 CAPLUS

L10 ANSWER 126 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1998:680662 CAPLUS
DN 130:75781
TI Combination alpha-interferon and lamivudine therapy for
alpha-interferon-resistant chronic **hepatitis** B infection:
results of a pilot study
AU Mutimer, David; Naoumov, Nicolai; Honkoop, Pieter; Marinos, George;
Ahmed,
Monz; de Man, Robert; McPhillips, Penny; Johnson, Mark; Williams, Roger;
Elias, Elwyn; Schalm, Solko
CS Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Birmingham, B15
2TH, UK
SO J. Hepatol. (1998), 28(6), 923-929
CODEN: JOHEEC; ISSN: 0168-8278
PB Munksgaard International Publishers Ltd.
DT Journal

LA English

RE.CNT 23

RE

- (4) Cui, L; J Clin Invest 1995, V95, P555 CAPLUS
- (6) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
- (7) Eron, J; N Engl J Med 1995, V333, P1662 CAPLUS
- (10) Harker, A; J Chromatogr 1994, V657, P227 CAPLUS
- (12) Honkoop, P; Hepatology 1997, V26, P211 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 127 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:623468 CAPLUS

DN 130:20231

TI Robustaflavone, a potential non-nucleoside anti-**hepatitis B** agent

AU Zembower, David E.; Lin, Yuh-Meei; Flavin, Michael T.; Fa-Ching Chen; Korba, Brent E.

CS MediChem Research, Inc., Lemont, IL, 60439, USA

SO Antiviral Res. (1998), 39(2), 81-88

CODEN: ARSRDR; ISSN: 0166-3542

PB Elsevier Science B.V.

DT Journal

LA English

RE.CNT 27

RE

- (4) Belen'kii, M; Antiviral Res 1994, V25, P1 CAPLUS
- (5) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS
- (7) Chen, F; Phytochemistry 1974, V13, P276 CAPLUS
- (8) Chen, F; Phytochemistry 1975, V14, P1644 CAPLUS
- (9) Chen, F; Phytochemistry 1975, V14, P300 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 128 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:584963 CAPLUS

DN 129:298066

TI Lamivudine treatment can restore T cell responsiveness in chronic **hepatitis B**

AU Boni, Carolina; Bertoletti, Antonio; Penna, Amalia; Cavalli, Albertina; Pilli, Massimo; Urbani, Simona; Scognamiglio, Paola; Boehme, Richard; Panebianco, Ruggero; Fiaccadori, Franco; Ferrari, Carlo

CS Laboratorio di Immunopatologia Virale, Divisione Malattie Infettive, Universita di Parma, Azienda Ospedaliera di Parma, Parma, Italy

SO J. Clin. Invest. (1998), 102(5), 968-975

CODEN: JCINAO; ISSN: 0021-9738

PB Rockefeller University Press

DT Journal

LA English

L10 ANSWER 129 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:582473 CAPLUS

DN 129:339487

TI Lamivudine inhibits **hepatitis B** virus replication in kidney graft recipients

AU Goffin, Eric; Horsmans, Yves; Cornu, Chantal; Squifflet, Jean-Paul; Pirson, Yves

CS Departments of Nephrology, Hepatology, Virology, and Renal Transplantation, Louvain Medical School, Hopital Saint-Luc, Brussels, 1200, Belg.

LA English

RE.CNT 23

RE

- (4) Cui, L; J Clin Invest 1995, V95, P555 CAPLUS
- (6) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
- (7) Eron, J; N Engl J Med 1995, V333, P1662 CAPLUS
- (10) Harker, A; J Chromatogr 1994, V657, P227 CAPLUS
- (12) Honkoop, P; Hepatology 1997, V26, P211 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 127 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:623468 CAPLUS

DN 130:20231

TI Robustaflavone, a potential non-nucleoside anti-**hepatitis B** agent

AU Zembower, David E.; Lin, Yuh-Meei; Flavin, Michael T.; Fa-Ching Chen; Korba, Brent E.

CS MediChem Research, Inc., Lemont, IL, 60439, USA

SO Antiviral Res. (1998), 39(2), 81-88

CODEN: ARSRDR; ISSN: 0166-3542

PB Elsevier Science B.V.

DT Journal

LA English

RE.CNT 27

RE

- (4) Belen'kii, M; Antiviral Res 1994, V25, P1 CAPLUS
- (5) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS
- (7) Chen, F; Phytochemistry 1974, V13, P276 CAPLUS
- (8) Chen, F; Phytochemistry 1975, V14, P1644 CAPLUS
- (9) Chen, F; Phytochemistry 1975, V14, P300 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 128 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:584963 CAPLUS

DN 129:298066

TI Lamivudine treatment can restore T cell responsiveness in chronic **hepatitis B**

AU Boni, Carolina; Bertoletti, Antonio; Penna, Amalia; Cavalli, Albertina; Pilli, Massimo; Urbani, Simona; Scognamiglio, Paola; Boehme, Richard; Panebianco, Ruggero; Fiaccadori, Franco; Ferrari, Carlo

CS Laboratorio di Immunopatologia Virale, Divisione Malattie Infettive, Universita di Parma, Azienda Ospedaliera di Parma, Parma, Italy

SO J. Clin. Invest. (1998), 102(5), 968-975

CODEN: JCINAO; ISSN: 0021-9738

PB Rockefeller University Press

DT Journal

LA English

L10 ANSWER 129 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:582473 CAPLUS

DN 129:339487

TI Lamivudine inhibits **hepatitis B** virus replication in kidney graft recipients

AU Goffin, Eric; Horsmans, Yves; Cornu, Chantal; Squifflet, Jean-Paul; Pirson, Yves

CS Departments of Nephrology, Hepatology, Virology, and Renal Transplantation, Louvain Medical School, Hopital Saint-Luc, Brussels, 1200, Belg.

SO Transplantation (1998), 66(3), 407-409
CODEN: TRPLAU; ISSN: 0041-1337
PB Williams & Wilkins
DT Journal
LA English

L10 ANSWER 130 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:555499 CAPLUS

DN 129:285629

TI Prophylaxis against **hepatitis** B recurrence following liver transplantation using combination lamivudine and **hepatitis** B immune globulin

AU Markovitz, Jay S.; Martin, Paul; Conrad, Andrew J.; Markmann, James; Seu, Philip; Yersiz, Hasan; Goss, John; Schmidt, Peter; Pakrasi, Anita; Artinian, Lucy; Murray, Natalie G. B.; Imagawa, David K.; Holt, Curtis; Goldstein, Leonard I.; Stribling, Rise; Busuttil, Ronald W.

CS The Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, UCLA Medical Center, Los Angeles, CA, USA

SO Hepatology (Philadelphia) (1998), 28(2), 585-589

CODEN: HPTLDD; ISSN: 0270-9139

PB W. B. Saunders Co.

DT Journal

LA English

L10 ANSWER 131 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:514668 CAPLUS

DN 129:254232

TI Experience with lamivudine against **hepatitis** B virus

AU Jaeckel, Elmar; Manns, Michael P.

CS Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Hannover, D-30625, Germany

SO Intervirology (1998), Volume Date 1997, 40(5-6), 322-336

CODEN: IVRYAK; ISSN: 0300-5526

PB S. Karger AG

DT Journal; General Review

LA English

L10 ANSWER 132 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:480978 CAPLUS

DN 129:254380

TI A one-year trial of lamivudine for chronic **hepatitis** B

AU Lai, Ching-Lung; Chien, Rong-Nan; Leung, Nancy W. Y.; Chang, Ting-Tsung; Guan, Richard; Tai, Dar-In; Ng, Keng-Yeen; Wu, Pui-Chee; Dent, Julie C.; Barber, Judy; Stephenson, Sally L.; Gray, D. Fraser

CS Department of Medicine, Queen Mary Hospital, Hong Kong, Peop. Rep. China

SO N. Engl. J. Med. (1998), 339(2), 61-68

CODEN: NEJMAG; ISSN: 0028-4793

PB Massachusetts Medical Society

DT Journal

LA English

L10 ANSWER 133 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:471054 CAPLUS

DN 129:225320

TI Efficacy of lamivudine in controlling **hepatitis** B virus recurrence after liver transplantation

AU Nery, Jose R.; Weppler, Deborah; Rodriguez, Miguel; Ruiz, Phillip; Schiff,

SO Transplantation (1998), 66(3), 407-409
CODEN: TRPLAU; ISSN: 0041-1337
PB Williams & Wilkins
DT Journal
LA English

L10 ANSWER 130 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1998:555499 CAPLUS
DN 129:285629
TI Prophylaxis against **hepatitis** B recurrence following liver
transplantation using combination lamivudine and **hepatitis** B
immune globulin
AU Markovitz, Jay S.; Martin, Paul; Conrad, Andrew J.; Markmann, James; Seu,
Philip; Yersiz, Hasan; Goss, John; Schmidt, Peter; Pakrasi, Anita;
Artinian, Lucy; Murray, Natalie G. B.; Imagawa, David K.; Holt, Curtis;
Goldstein, Leonard I.; Stribling, Rise; Busuttil, Ronald W.
CS The Dumont-UCLA Transplant Center, Division of Liver and Pancreas
Transplantation, UCLA Medical Center, Los Angeles, CA, USA
SO Hepatology (Philadelphia) (1998), 28(2), 585-589
CODEN: HPTLDD; ISSN: 0270-9139
PB W. B. Saunders Co.
DT Journal
LA English

L10 ANSWER 131 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1998:514668 CAPLUS
DN 129:254232
TI Experience with lamivudine against **hepatitis** B virus
AU Jaeckel, Elmar; Manns, Michael P.
CS Department of Gastroenterology and Hepatology, Medizinische Hochschule
Hannover, Hannover, D-30625, Germany
SO Intervirology (1998), Volume Date 1997, 40(5-6), 322-336
CODEN: IVRYAK; ISSN: 0300-5526
PB S. Karger AG
DT Journal; General Review
LA English

L10 ANSWER 132 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1998:480978 CAPLUS
DN 129:254380
TI A one-year trial of lamivudine for chronic **hepatitis** B
AU Lai, Ching-Lung; Chien, Rong-Nan; Leung, Nancy W. Y.; Chang, Ting-Tsung;
Guan, Richard; Tai, Dar-In; Ng, Keng-Yeen; Wu, Pui-Chee; Dent, Julie C.;
Barber, Judy; Stephenson, Sally L.; Gray, D. Fraser
CS Department of Medicine, Queen Mary Hospital, Hong Kong, Peop. Rep. China
SO N. Engl. J. Med. (1998), 339(2), 61-68
CODEN: NEJMAG; ISSN: 0028-4793
PB Massachusetts Medical Society
DT Journal
LA English

L10 ANSWER 133 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1998:471054 CAPLUS
DN 129:225320
TI Efficacy of lamivudine in controlling **hepatitis** B virus
recurrence after liver transplantation
AU Nery, Jose R.; Weppler, Deborah; Rodriguez, Miguel; Ruiz, Phillip;
Schiff,

Eugene R.; Tzakis, Andreas G.
 CS Department of Surgery, Division of Transplantation; School of Medicine,
 University of Miami, Miami, FL, 33136, USA
 SO Transplantation (1998), 65(12), 1615-1621
 CODEN: TRPLAU; ISSN: 0041-1337
 PB Williams & Wilkins
 DT Journal
 LA English

L10 ANSWER 134 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:436524 CAPLUS
 DN 129:170141
 TI Anti-**hepatitis** B virus activity and metabolism of
 2',3'-dideoxy-2',3'-didehydro-.beta.-L(-)-5-fluorocytidine
 AU Zhu, Yong-Lian; Dutschman, Ginger E.; Liu, Shwu-Huey; Bridges, Edward G.;
 Cheng, Yung-Chi
 CS Department Pharmacology, Yale University School Medicine, New Haven, CT,
 06520, USA
 SO Antimicrob. Agents Chemother. (1998), 42(7), 1805-1810
 CODEN: AMACCQ; ISSN: 0066-4804
 PB American Society for Microbiology
 DT Journal
 LA English

L10 ANSWER 135 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:384811 CAPLUS
 DN 129:103844
 TI Emergence and takeover of YMDD motif mutant **hepatitis** B virus
 during long-term lamivudine therapy and re-takeover by wild type after
 cessation of therapy
 AU Chayama, Kazuaki; Suzuki, Yoshiyuki; Kobayashi, Masahiro; Kobayashi,
 Mizuho; Tsubota, Akihito; Hashimoto, Michie; Miyano, Yukiko; Koike,
 Hiromi; Kobayashi, Mariko; Koida, Isao; Arase, Yasuji; Saitoh, Satoshi;
 Murashima, Naoya; Ikeda, Kenji; Kumada, Hiromitsu
 CS Department of Gastroenterology, Memorial Institute for Medical Research,
 Toranomon Hospital, Okinaka, Tokyo, 105, Japan
 SO Hepatology (Philadelphia) (1998), 27(6), 1711-1716
 CODEN: HPTLD9; ISSN: 0270-9139
 PB W. B. Saunders Co.
 DT Journal
 LA English

L10 ANSWER 136 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:384808 CAPLUS
 DN 129:157479
 TI Identification and characterization of mutations in **hepatitis** B
 virus resistant to lamivudine
 AU Allen, Marchelle I.; Deslauriers, Manon; Andrews, C. Webster; Tipples,
 Graham A.; Walters, Kathie-Anne; Tyrrell, David L. J.; Brown, Nathaniel;
 Condreay, Lynn D.
 CS Department of Virology, Glaxo Wellcome Inc., Research Triangle Park, NC,
 27709-3398, USA
 SO Hepatology (Philadelphia) (1998), 27(6), 1670-1677
 CODEN: HPTLD9; ISSN: 0270-9139
 PB W. B. Saunders Co.
 DT Journal
 LA English

Eugene R.; Tzakis, Andreas G.
 CS Department of Surgery, Division of Transplantation; School of Medicine,
 University of Miami, Miami, FL, 33136, USA
 SO Transplantation (1998), 65(12), 1615-1621
 CODEN: TRPLAU; ISSN: 0041-1337
 PB Williams & Wilkins
 DT Journal
 LA English

L10 ANSWER 134 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:436524 CAPLUS
 DN 129:170141
 TI Anti-**hepatitis** B virus activity and metabolism of
 2',3'-dideoxy-2',3'-didehydro-.beta.-L(-)-5-fluorocytidine
 AU Zhu, Yong-Lian; Dutschman, Ginger E.; Liu, Shwu-Huey; Bridges, Edward G.;
 Cheng, Yung-Chi
 CS Department Pharmacology, Yale University School Medicine, New Haven, CT,
 06520, USA
 SO Antimicrob. Agents Chemother. (1998), 42(7), 1805-1810
 CODEN: AMACCQ; ISSN: 0066-4804
 PB American Society for Microbiology
 DT Journal
 LA English

L10 ANSWER 135 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:384811 CAPLUS
 DN 129:103844
 TI Emergence and takeover of YMDD motif mutant **hepatitis** B virus
 during long-term lamivudine therapy and re-takeover by wild type after
 cessation of therapy
 AU Chayama, Kazuaki; Suzuki, Yoshiyuki; Kobayashi, Masahiro; Kobayashi,
 Mizuho; Tsubota, Akihito; Hashimoto, Michie; Miyano, Yukiko; Koike,
 Hiromi; Kobayashi, Mariko; Koida, Isao; Arase, Yasuji; Saitoh, Satoshi;
 Murashima, Naoya; Ikeda, Kenji; Kumada, Hiromitsu
 CS Department of Gastroenterology, Memorial Institute for Medical Research,
 Toranomon Hospital, Okinaka, Tokyo, 105, Japan
 SO Hepatology (Philadelphia) (1998), 27(6), 1711-1716
 CODEN: HPTLD9; ISSN: 0270-9139
 PB W. B. Saunders Co.
 DT Journal
 LA English

L10 ANSWER 136 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:384808 CAPLUS
 DN 129:157479
 TI Identification and characterization of mutations in **hepatitis** B
 virus resistant to lamivudine
 AU Allen, Marchelle I.; Deslauriers, Manon; Andrews, C. Webster; Tipples,
 Graham A.; Walters, Kathie-Anne; Tyrrell, David L. J.; Brown, Nathaniel;
 Condreay, Lynn D.
 CS Department of Virology, Glaxo Wellcome Inc., Research Triangle Park, NC,
 27709-3398, USA
 SO Hepatology (Philadelphia) (1998), 27(6), 1670-1677
 CODEN: HPTLD9; ISSN: 0270-9139
 PB W. B. Saunders Co.
 DT Journal
 LA English

L10 ANSWER 137 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:289344 CAPLUS
 DN 129:49250
 TI Role of additional mutations outside the YMDD motif of **hepatitis**
 B virus polymerase in L(-)SddC (3TC) resistance
 AU Fu, Lei; Cheng, Yung-Chi
 CS Department of Pharmacology, Yale University School of Medicine, New
 Haven,
 CT, 06520, USA
 SO Biochem. Pharmacol. (1998), 55(10), 1567-1572
 CODEN: BCPA6; ISSN: 0006-2952
 PB Elsevier Science Inc.
 DT Journal
 LA English

L10 ANSWER 138 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:96111 CAPLUS
 DN 128:225741
 TI The **hepatitis** B virus M539V polymerase variation responsible for
 3TC resistance also confers cross-resistance to other nucleoside analogs
 AU Ladner, S. K.; Miller, T. J.; Otto, M. J.; King, R. W.
 CS Avid Therapeutics, Philadelphia, PA, 19104, USA
 SO Antiviral Chem. Chemother. (1998), 9(1), 65-72
 CODEN: ACCHEH; ISSN: 0956-3202
 PB International Medical Press
 DT Journal
 LA English

L10 ANSWER 139 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:23330 CAPLUS
 DN 128:149229
 TI Efficacy and safety of lamivudine on replication of recurrent
hepatitis B after cadaveric renal transplantation
 AU Rostaing, Lionel; Henry, Sabine; Cisterne, Jean-Marc; Duffaut, Michel;
 Icart, Josette; Durand, Dominique
 CS Multi-Organ Transplant Unit, Virology Laboratory, Toulouse University
 Hospital, Toulouse, Fr.
 SO Transplantation (1997), 64(11), 1624-1627
 CODEN: TRPLAU; ISSN: 0041-1337
 PB Williams & Wilkins
 DT Journal
 LA English

L10 ANSWER 140 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:718044 CAPLUS
 DN 128:19356
 TI Line probe assay [LiPA test strip] for genotyping and detecting
HBV in blood serum
 IN Stuyver, Lieven; Rossau, Rudi; Maertens, Geert
 PA Innogenetics N.V., Belg.; Stuyver, Lieven; Rossau, Rudi; Maertens, Geert
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9740193	A2	19971030	WO 1997-EP2002	19970421

L10 ANSWER 137 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:289344 CAPLUS
 DN 129:49250
 TI Role of additional mutations outside the YMDD motif of **hepatitis**
 B virus polymerase in L(-)SddC (3TC) resistance
 AU Fu, Lei; Cheng, Yung-Chi
 CS Department of Pharmacology, Yale University School of Medicine, New
 Haven,
 CT, 06520, USA
 SO Biochem. Pharmacol. (1998), 55(10), 1567-1572
 CODEN: BCPA6; ISSN: 0006-2952
 PB Elsevier Science Inc.
 DT Journal
 LA English

L10 ANSWER 138 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:96111 CAPLUS
 DN 128:225741
 TI The **hepatitis** B virus M539V polymerase variation responsible for
 3TC resistance also confers cross-resistance to other nucleoside analogs
 AU Ladner, S. K.; Miller, T. J.; Otto, M. J.; King, R. W.
 CS Avid Therapeutics, Philadelphia, PA, 19104, USA
 SO Antiviral Chem. Chemother. (1998), 9(1), 65-72
 CODEN: ACCHEH; ISSN: 0956-3202
 PB International Medical Press
 DT Journal
 LA English

L10 ANSWER 139 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:23330 CAPLUS
 DN 128:149229
 TI Efficacy and safety of lamivudine on replication of recurrent
hepatitis B after cadaveric renal transplantation
 AU Rostaing, Lionel; Henry, Sabine; Cisterne, Jean-Marc; Duffaut, Michel;
 Icart, Josette; Durand, Dominique
 CS Multi-Organ Transplant Unit, Virology Laboratory, Toulouse University
 Hospital, Toulouse, Fr.
 SO Transplantation (1997), 64(11), 1624-1627
 CODEN: TRPLAU; ISSN: 0041-1337
 PB Williams & Wilkins
 DT Journal
 LA English

L10 ANSWER 140 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:718044 CAPLUS
 DN 128:19356
 TI Line probe assay [LiPA test strip] for genotyping and detecting
HBV in blood serum
 IN Stuyver, Lieven; Rossau, Rudi; Maertens, Geert
 PA Innogenetics N.V., Belg.; Stuyver, Lieven; Rossau, Rudi; Maertens, Geert
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9740193	A2	19971030	WO 1997-EP2002	19970421

WO 9740193 A3 19980507
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,
 VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
 ML, MR, NE, SN, TD, TG
 AU 9727662 A1 19971112 AU 1997-27662 19970421
 EP 914472 A2 19990512 EP 1997-921677 19970421
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 PRAI EP 1996-870053 19960419
 WO 1997-EP2002 19970421

L10 ANSWER 141 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:474419 CAPLUS
 DN 127:130528
 TI Lamivudine treatment of advanced and decompensated liver disease due to
 hepatitis B
 AU Van Thiel, David H.; Friedlander, Lois; Robert, R. N.; Kania, J.; Peter,
 M.D.; Molloy, J.; Hassanein, Tarek; Wahlstrom, Eric; Faruki, Hawazin
 CS Department of Medicine, University of Kentucky School of Medicine,
 Lexington, KY, USA
 SO Hepato-Gastroenterology (1997), 44(15), 808-812
 CODEN: HEGAD4; ISSN: 0172-6390
 PB H.G.E. Update Medical Publishing
 DT Journal
 LA English

L10 ANSWER 142 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:472373 CAPLUS
 DN 127:130526
 TI Synergistic inhibition of hepadnaviral replication by lamivudine in
 combination with penciclovir in vitro
 AU Colledge, Danni; Locarnini, Stephen; Shaw, Tim
 CS Victorian Infectious Diseases Reference Laboratories, Fairfield Hospital,
 Fairfield, 3078, Australia
 SO Hepatology (Philadelphia) (1997), 26(1), 216-225
 CODEN: HPTLD9; ISSN: 0270-9139
 PB Saunders
 DT Journal
 LA English

L10 ANSWER 143 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:228422 CAPLUS
 DN 126:271670
 TI Liver transplantation and **hepatitis B**: treatment and prophylaxis
 of reinfection with new **antiviral** agents
 AU Krueger, Martin; Manns, Michael P.
 CS Department of Gastroenterology and Hepatology, Medizinische Hannover,
 Hannover, D-30623, Germany
 SO Antiviral Ther. (1996), 1(Suppl. 4, Therapies for Viral Hepatitis), 71-75
 CODEN: ANTHFA; ISSN: 1359-6535
 PB International Medical Press
 DT Journal; General Review
 LA English

WO 9740193 A3 19980507
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,
 VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
 ML, MR, NE, SN, TD, TG
 AU 9727662 A1 19971112 AU 1997-27662 19970421
 EP 914472 A2 19990512 EP 1997-921677 19970421
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 PRAI EP 1996-870053 19960419
 WO 1997-EP2002 19970421

L10 ANSWER 141 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:474419 CAPLUS
 DN 127:130528
 TI Lamivudine treatment of advanced and decompensated liver disease due to
 hepatitis B
 AU Van Thiel, David H.; Friedlander, Lois; Robert, R. N.; Kania, J.; Peter,
 M.D.; Molloy, J.; Hassanein, Tarek; Wahlstrom, Eric; Faruki, Hawazin
 CS Department of Medicine, University of Kentucky School of Medicine,
 Lexington, KY, USA
 SO Hepato-Gastroenterology (1997), 44(15), 808-812
 CODEN: HEGAD4; ISSN: 0172-6390
 PB H.G.E. Update Medical Publishing
 DT Journal
 LA English

L10 ANSWER 142 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:472373 CAPLUS
 DN 127:130526
 TI Synergistic inhibition of hepadnaviral replication by lamivudine in
 combination with penciclovir in vitro
 AU Colledge, Danni; Locarnini, Stephen; Shaw, Tim
 CS Victorian Infectious Diseases Reference Laboratories, Fairfield Hospital,
 Fairfield, 3078, Australia
 SO Hepatology (Philadelphia) (1997), 26(1), 216-225
 CODEN: HPTLD9; ISSN: 0270-9139
 PB Saunders
 DT Journal
 LA English

L10 ANSWER 143 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:228422 CAPLUS
 DN 126:271670
 TI Liver transplantation and **hepatitis B**: treatment and prophylaxis
 of reinfection with new **antiviral** agents
 AU Krueger, Martin; Manns, Michael P.
 CS Department of Gastroenterology and Hepatology, Medizinische Hannover,
 Hannover, D-30623, Germany
 SO Antiviral Ther. (1996), 1(Suppl. 4, Therapies for Viral Hepatitis), 71-75
 CODEN: ANTHFA; ISSN: 1359-6535
 PB International Medical Press
 DT Journal; General Review
 LA English

L10 ANSWER 144 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:189168 CAPLUS
 DN 126:233148
 TI Beneficial effect of lamivudine in recurrent **hepatitis** B after
 liver transplantation
 AU Ben-Ari, Ziv; Shmueli, Dan; Mor, Eitan; Shapira, Zaki; Tur-Kaspa, Ran
 CS Departments of Transplantation and Surgery B, Rabin Medical Center, Liver
 Institute and Internal Depat D, Petah Tiqva, 49 100, Israel
 SO Transplantation (1997), 63(3), 393-403
 CODEN: TRPLAU; ISSN: 0041-1337
 PB Williams & Wilkins
 DT Journal
 LA English

L10 ANSWER 145 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:145208 CAPLUS
 DN 126:139863
 TI Stabilized nucleotides from nucleosides with anti-**hepatitis** B
 virus activity, nucleosides and nucleotides for treatment of
hepatitis B virus infection, and compound preparation
 IN Schinazi, Raymond F.; Sommadossi, Jean-Pierre; Grosselin, Gilles; Imbach,
 Jean-Louis
 PA Emory University, USA; Uab Research Foundation; Centre National de la
 Recherche Scientifique
 SO PCT Int. Appl., 51PP
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640164	A1	19961219	WO 1996-US10026	19960607
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	CA 2219132	AA	19961219	CA 1996-2219132	19960607
	AU 9661707	A1	19961230	AU 1996-61707	19960607
	AU 722214	B2	20000727		
	EP 831852	A1	19980401	EP 1996-919349	19960607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI				
	JP 11507381	T2	19990629	JP 1996-502163	19960607
	US 6245749	B1	20010612	US 1998-112878	19980709
PRAI	US 1995-485716	A	19950607		
	US 1994-320461	B2	19941007		
	WO 1996-US10026	W	19960607		
OS	MARPAT 126:139863				

L10 ANSWER 146 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:100922 CAPLUS
 DN 126:180871
 TI Lamivudine is effective in suppressing **hepatitis** B virus DNA in
 Chinese **hepatitis** B surface antigen carriers: a
 placebo-controlled trial
 AU Lai, Ching-Lung; Ching, Chi-Kong; Tung, Angus Kwong-Ming; Li, Eileen;
 Young, John; Andrew, Hill; Wong, Benjamin Chun-Yu; Dent, Julie; Wu,
 Pui-Chee

L10 ANSWER 144 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:189168 CAPLUS
 DN 126:233148
 TI Beneficial effect of lamivudine in recurrent **hepatitis** B after
 liver transplantation
 AU Ben-Ari, Ziv; Shmueli, Dan; Mor, Eitan; Shapira, Zaki; Tur-Kaspa, Ran
 CS Departments of Transplantation and Surgery B, Rabin Medical Center, Liver
 Institute and Internal Depat D, Petah Tiqva, 49 100, Israel
 SO Transplantation (1997), 63(3), 393-403
 CODEN: TRPLAU; ISSN: 0041-1337
 PB Williams & Wilkins
 DT Journal
 LA English

L10 ANSWER 145 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:145208 CAPLUS
 DN 126:139863
 TI Stabilized nucleotides from nucleosides with anti-**hepatitis** B
 virus activity, nucleosides and nucleotides for treatment of
hepatitis B virus infection, and compound preparation
 IN Schinazi, Raymond F.; Sommadossi, Jean-Pierre; Grosselin, Gilles; Imbach,
 Jean-Louis
 PA Emory University, USA; Uab Research Foundation; Centre National de la
 Recherche Scientifique
 SO PCT Int. Appl., 51PP
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640164	A1	19961219	WO 1996-US10026	19960607
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	CA 2219132	AA	19961219	CA 1996-2219132	19960607
	AU 9661707	A1	19961230	AU 1996-61707	19960607
	AU 722214	B2	20000727		
	EP 831852	A1	19980401	EP 1996-919349	19960607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI				
	JP 11507381	T2	19990629	JP 1996-502163	19960607
	US 6245749	B1	20010612	US 1998-112878	19980709
PRAI	US 1995-485716	A	19950607		
	US 1994-320461	B2	19941007		
	WO 1996-US10026	W	19960607		
OS	MARPAT 126:139863				

L10 ANSWER 146 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1997:100922 CAPLUS
 DN 126:180871
 TI Lamivudine is effective in suppressing **hepatitis** B virus DNA in
 Chinese **hepatitis** B surface antigen carriers: a
 placebo-controlled trial
 AU Lai, Ching-Lung; Ching, Chi-Kong; Tung, Angus Kwong-Ming; Li, Eileen;
 Young, John; Andrew, Hill; Wong, Benjamin Chun-Yu; Dent, Julie; Wu,
 Pui-Chee

CS Department of Medicine, University of Hong Kong, Hong Kong
SO Hepatology (Philadelphia) (1997), 25(1), 241-244
CODEN: HPTLD9; ISSN: 0270-9139
PB Saunders
DT Journal
LA English

L10 ANSWER 147 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1997:92430 CAPLUS
DN 126:184874
TI Impact of complete inhibition of viral replication on the cellular immune response in chronic **hepatitis** B virus infection
AU Marinos, George; Naoumov, Nikolai V.; Williams, Roger
CS Institute of Liver Studies, King's College School of Medicine and Dentistry, London, UK
SO Hepatology (Philadelphia) (1996), 24(5), 991-995
CODEN: HPTLD9; ISSN: 0270-9139
PB Saunders
DT Journal
LA English

L10 ANSWER 148 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1997:8478 CAPLUS
DN 126:42321
TI Efficacy of lamivudine in chronic **hepatitis** B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
AU Bain, Vincent G.; Kneteman, Norman M.; Ma, Mang M.; Gutfreund, Klaus; Shapiro, James A.; Fischer, Karl; Tipples, Graham; Lee, Helen; Jewell, Laurence D.; Tyrrell, D. Lorne
CS The Departments of Medicine, Surgery, Medical Microbiology and Immunology, and Pathology, University of Alberta, Edmonton, AB, Can.
SO Transplantation (1996), 62(10), 1456-1462
CODEN: TRPLAU; ISSN: 0041-1337
PB Williams & Wilkins
DT Journal
LA English

L10 ANSWER 149 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1996:682645 CAPLUS
DN 125:316343
TI Effects of lamivudine on replication of **hepatitis** B virus in HIV-infected men
AU Benhamou, Yves; Katlama, Christine; Lunel, Françoise; Coutellier, Anne; Dohin, Elisabeth; Hamm, Nathalie; Tubiana, Roland; Herson, Serge; Poynard, Thierry; Opolon, Pietre
CS Groupe Hosp. Pitie-Salpetriere, Paris, Fr.
SO Ann. Intern. Med. (1996), 125(9), 705-712
CODEN: AIMEAS; ISSN: 0003-4819
DT Journal
LA English

L10 ANSWER 150 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1996:584863 CAPLUS
DN 125:237700
TI Selection of mutations in the **hepatitis** B virus polymerase

CS Department of Medicine, University of Hong Kong, Hong Kong
SO Hepatology (Philadelphia) (1997), 25(1), 241-244
CODEN: HPTLD9; ISSN: 0270-9139
PB Saunders
DT Journal
LA English

L10 ANSWER 147 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1997:92430 CAPLUS
DN 126:184874
TI Impact of complete inhibition of viral replication on the cellular immune response in chronic **hepatitis** B virus infection
AU Marinos, George; Naoumov, Nikolai V.; Williams, Roger
CS Institute of Liver Studies, King's College School of Medicine and Dentistry, London, UK
SO Hepatology (Philadelphia) (1996), 24(5), 991-995
CODEN: HPTLD9; ISSN: 0270-9139
PB Saunders
DT Journal
LA English

L10 ANSWER 148 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1997:8478 CAPLUS
DN 126:42321
TI Efficacy of lamivudine in chronic **hepatitis** B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
AU Bain, Vincent G.; Kneteman, Norman M.; Ma, Mang M.; Gutfreund, Klaus; Shapiro, James A.; Fischer, Karl; Tipples, Graham; Lee, Helen; Jewell, Laurence D.; Tyrrell, D. Lorne
CS The Departments of Medicine, Surgery, Medical Microbiology and Immunology, and Pathology, University of Alberta, Edmonton, AB, Can.
SO Transplantation (1996), 62(10), 1456-1462
CODEN: TRPLAU; ISSN: 0041-1337
PB Williams & Wilkins
DT Journal
LA English

L10 ANSWER 149 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1996:682645 CAPLUS
DN 125:316343
TI Effects of lamivudine on replication of **hepatitis** B virus in HIV-infected men
AU Benhamou, Yves; Katlama, Christine; Lunel, Françoise; Coutellier, Anne; Dohin, Elisabeth; Hamm, Nathalie; Tubiana, Roland; Herson, Serge; Poynard, Thierry; Opolon, Pietre
CS Groupe Hosp. Pitie-Salpetriere, Paris, Fr.
SO Ann. Intern. Med. (1996), 125(9), 705-712
CODEN: AIMEAS; ISSN: 0003-4819
DT Journal
LA English

L10 ANSWER 150 OF 160 CAPLUS COPYRIGHT 2001 ACS
AN 1996:584863 CAPLUS
DN 125:237700
TI Selection of mutations in the **hepatitis** B virus polymerase

during therapy of transplant recipients with lamivudine

AU Ling, Roger; Mutimer, David; Ahmed, Monz; Boxall, Elizabeth H.; Elias, Elwyn; Dusheiko, Geoffrey M.; Harrison, Tim J.

CS School Medicine, Royal Free Hospital, London, NW3 2PF, UK

SO Hepatology (Philadelphia) (1996), 24(3), 711-713

CODEN: HPTLD9; ISSN: 0270-9139

DT Journal

LA English

L10 ANSWER 151 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:503607 CAPLUS

DN 125:211868

TI Anti-HIV and anti-**HBV** activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative

CF 1109

AU Balzarini, Jan; Wedgwood, O.; Kruining, J.; Pelemans, Heidi; Heijntink, R.;

De Clercq, Erik; McGuigan, C.

CS Rega Inst. Med. Res., Kathol. Univ. Leuven, Louvain, B-3000, Belg.

SO Biochem. Biophys. Res. Commun. (1996), 225(2), 363-369

CODEN: BBRCA9; ISSN: 0006-291X

DT Journal

LA English

L10 ANSWER 152 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:330477 CAPLUS

DN 125:75411

TI DNA polymerase activity of **hepatitis B** virus particles: differential inhibition by L-enantiomers of nucleotide analogs

AU Davis, Michelle G.; Wilson, Jeanne E.; VanDraanen, Nanine A.; Miller, Wayne H.; Freeman, George A.; Daluge, Susan M.; Boyd, Frank L.;

Aulabaugh, Ann E.; Painter, George R.; et al.

CS Glaxo Wellcome Inc., Research Triangle Park, NC 27709, USA

SO Antiviral Res. (1996), 30(2,3), 133-145

CODEN: ARSRDR; ISSN: 0166-3542

DT Journal

LA English

L10 ANSWER 153 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:200483 CAPLUS

DN 124:278119

TI In vitro evaluation of combination therapies against **hepatitis B** virus replication

AU Korba, Brent E.

CS Georgetown University, Division of Molecular Virology and Immunology, Rockville, USA

SO Antiviral Res. (1996), 29(1), 49-51

CODEN: ARSRDR; ISSN: 0166-3542

DT Journal

LA English

L10 ANSWER 154 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:143766 CAPLUS

DN 124:249564

TI Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks

AU Rajagopalan, Prabhu; Boudinot, F. Douglas; Chu, Chunk G.; Tennant, Bud C.;

during therapy of transplant recipients with lamivudine
AU Ling, Roger; Mutimer, David; Ahmed, Monz; Boxall, Elizabeth H.; Elias,
Elwyn; Dusheiko, Geoffrey M.; Harrison, Tim J.
CS School Medicine, Royal Free Hospital, London, NW3 2PF, UK
SO Hepatology (Philadelphia) (1996), 24(3), 711-713
CODEN: HPTLD9; ISSN: 0270-9139
DT Journal
LA English

L10 ANSWER 151 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:503607 CAPLUS

DN 125:211868

TI Anti-HIV and anti-**HBV** activity and resistance profile of
2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate
derivative

CF 1109

AU Balzarini, Jan; Wedgwood, O.; Kruining, J.; Pelemans, Heidi; Heijtkink,
R.;

De Clercq, Erik; McGuigan, C.

CS Rega Inst. Med. Res., Kathol. Univ. Leuven, Louvain, B-3000, Belg.

SO Biochem. Biophys. Res. Commun. (1996), 225(2), 363-369

CODEN: BBRC9; ISSN: 0006-291X

DT Journal

LA English

L10 ANSWER 152 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:330477 CAPLUS

DN 125:75411

TI DNA polymerase activity of **hepatitis B** virus particles:
differential inhibition by L-enantiomers of nucleotide analogs

AU Davis, Michelle G.; Wilson, Jeanne E.; VanDraanen, Nanine A.; Miller,
Wayne H.; Freeman, George A.; Daluge, Susan M.; Boyd, Frank L.;
Aulabaugh,

Ann E.; Painter, George R.; et al.

CS Glaxo Wellcome Inc., Research Triangle Park, NC 27709, USA

SO Antiviral Res. (1996), 30(2,3), 133-145

CODEN: ARSRDR; ISSN: 0166-3542

DT Journal

LA English

L10 ANSWER 153 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:200483 CAPLUS

DN 124:278119

TI In vitro evaluation of combination therapies against **hepatitis B**
virus replication

AU Korba, Brent E.

CS Georgetown University, Division of Molecular Virology and Immunology,
Rockville, USA

SO Antiviral Res. (1996), 29(1), 49-51

CODEN: ARSRDR; ISSN: 0166-3542

DT Journal

LA English

L10 ANSWER 154 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:143766 CAPLUS

DN 124:249564

TI Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks

AU Rajagopalan, Prabhu; Boudinot, F. Douglas; Chu, Chunk G.; Tennant, Bud
C.;

Baldwin, Betty H.; Schinazi, Raymond F.
 CS Coll. Pharm., Univ. Georgia, Athens, GA, 30602, USA
 SO Antimicrob. Agents Chemother. (1996), 40(3), 642-5
 CODEN: AMACCQ; ISSN: 0066-4804
 DT Journal
 LA English

L10 ANSWER 155 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1996:49895 CAPLUS
 DN 124:164383
 TI A preliminary trial of lamivudine for chronic **hepatitis B** infection
 AU Dienstag, Jules L.; Perrillo, Robert P.; Schiff, Eugene R.; Bartholomew, Maria; Vicary, Catherine; Rubin, Marc
 CS Dep. Med., Harvard Med. Sch., Boston, MA, USA
 SO N. Engl. J. Med. (1995), 333(25), 1657-61
 CODEN: NEJMAG; ISSN: 0028-4793
 DT Journal
 LA English

L10 ANSWER 156 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1995:875381 CAPLUS
 DN 124:193342
 TI Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and **antiviral** activity in **hepatitis B**- and HIV-1-infected cells
 AU Xie, Hong; Voronkov, Michael; Liotta, Dennis C.; Korba, Brent A.; Schinazi, Raymond F.; Richman, Douglas D.; Hostetler, Karl Y.
 CS Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA
 SO Antiviral Res. (1995), 28(2), 113-20
 CODEN: ARSRDR; ISSN: 0166-3542
 DT Journal
 LA English

L10 ANSWER 157 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1994:499776 CAPLUS
 DN 121:99776
 TI Enantiomerically pure .beta.-D-dioxolane nucleosides with selective anti-**hepatitis B** virus (**HBV**) activity
 IN Schinazi, Raymond P.
 PA Emory University, USA
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9409793	A1	19940511	WO 1993-US10348	19931028
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5444063	A	19950822	US 1992-967460	19921028
	AU 9455419	A1	19940524	AU 1994-55419	19931028
	AU 693079	B2	19980625		

Baldwin, Betty H.; Schinazi, Raymond F.
 CS Coll. Pharm., Univ. Georgia, Athens, GA, 30602, USA
 SO Antimicrob. Agents Chemother. (1996), 40(3), 642-5
 CODEN: AMACCQ; ISSN: 0066-4804
 DT Journal
 LA English

L10 ANSWER 155 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1996:49895 CAPLUS
 DN 124:164383
 TI A preliminary trial of lamivudine for chronic **hepatitis B** infection
 AU Dienstag, Jules L.; Perrillo, Robert P.; Schiff, Eugene R.; Bartholomew, Maria; Vicary, Catherine; Rubin, Marc
 CS Dep. Med., Harvard Med. Sch., Boston, MA, USA
 SO N. Engl. J. Med. (1995), 333(25), 1657-61
 CODEN: NEJMAG; ISSN: 0028-4793
 DT Journal
 LA English

L10 ANSWER 156 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1995:875381 CAPLUS
 DN 124:193342
 TI Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and **antiviral** activity in **hepatitis B**- and HIV-1-infected cells
 AU Xie, Hong; Voronkov, Michael; Liotta, Dennis C.; Korba, Brent A.; Schinazi, Raymond F.; Richman, Douglas D.; Hostetler, Karl Y.
 CS Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA
 SO Antiviral Res. (1995), 28(2), 113-20
 CODEN: ARSRDR; ISSN: 0166-3542
 DT Journal
 LA English

L10 ANSWER 157 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1994:499776 CAPLUS
 DN 121:99776
 TI Enantiomerically pure .beta.-D-dioxolane nucleosides with selective anti-**hepatitis B** virus (**HBV**) activity
 IN Schinazi, Raymond P.
 PA Emory University, USA
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9409793	A1	19940511	WO 1993-US10348	19931028
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5444063	A	19950822	US 1992-967460	19921028
	AU 9455419	A1	19940524	AU 1994-55419	19931028
	AU 693079	B2	19980625		

EP 666749 A1 19950816 EP 1994-900424 19931028
 EP 666749 B1 19980415
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,
 SE
 JP 08507286 T2 19960806 JP 1993-511314 19931028
 JP 3117217 B2 20001211 JP 1994-511314 19931028
 PRAI US 1992-967460 A 19921028
 US 1990-622762 A2 19901205
 US 1992-935515 B2 19920825
 WO 1993-US10348 W 19931028
 OS MARPAT 121:99776

L10 ANSWER 158 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1994:289465 CAPLUS
 DN 120:289465
 TI Influence of stereochemistry on **antiviral** activities and
 resistance profiles of dideoxycytidine nucleosides
 AU Van Draanen, Nanine A.; Tisdale, Margaret; Parry, Nigel R.; Jansen,
 Robert; Dornsife, Ronna E.; Tuttle, Joel V.; Averett, Devron R.;
 Koszalka,
 George W.
 CS Div. Exp. Therapy, Burroughs Wellcome Co., Research Triangle Park, NC,
 27709, USA
 SO Antimicrob. Agents Chemother. (1994), 38(4), 868-71
 CODEN: AMACCQ; ISSN: 0066-4804
 DT Journal
 LA English

L10 ANSWER 159 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1993:93802 CAPLUS
 DN 118:93802
 TI The anti-**hepatitis** B virus activities, cytotoxicities, and
 anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-
 (hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
 AU Furman, Phillip A.; Davis, Michelle; Liotta, Dennis C.; Paff, Melanie;
 Frick, Lloyd W.; Nelson, Donald J.; Dornsife, Ronna E.; Wurster, J. A.;
 Wilson, Lawrence J.; et al.
 CS Div. Virol., Burroughs Wellcome Co., Research Triangle Park, NC, 27709,
 USA
 SO Antimicrob. Agents Chemother. (1992), 36(12), 2686-92
 CODEN: AMACCQ; ISSN: 0066-4804
 DT Journal
 LA English

L10 ANSWER 160 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1992:194772 CAPLUS
 DN 116:194772
 TI Synthesis of enantiomerically pure (2'R,5'S)-(-)-1-(2-
 hydroxymethyloxathiolan-5-yl)cytosine as a potent **antiviral**
 agent against **hepatitis** B virus (HBV) and human
 immunodeficiency virus (HIV)
 AU Beach, J. Warren; Jeong, Lak S.; Alves, Antonio J.; Pohl, Douglas; Kim,
 Hea O.; Chang, Chien Neng; Doong, Shin Lian; Schinazi, Raymond F.; Cheng,
 Yung Chi; Chu, Chung K.
 CS Coll. Pharm., Univ. Georgia, Athens, GA, 30602, USA
 SO J. Org. Chem. (1992), 57(8), 2217-19
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal

EP 666749 A1 19950816 EP 1994-900424 19931028
 EP 666749 B1 19980415
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,
 SE
 JP 08507286 T2 19960806 JP 1993-511314 19931028
 JP 3117217 B2 20001211 JP 1994-511314 19931028
 PRAI US 1992-967460 A 19921028
 US 1990-622762 A2 19901205
 US 1992-935515 B2 19920825
 WO 1993-US10348 W 19931028
 OS MARPAT 121:99776

 L10 ANSWER 158 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1994:289465 CAPLUS
 DN 120:289465
 TI Influence of stereochemistry on **antiviral** activities and
 resistance profiles of dideoxycytidine nucleosides
 AU Van Draanen, Nanine A.; Tisdale, Margaret; Parry, Nigel R.; Jansen,
 Robert; Dornsife, Ronna E.; Tuttle, Joel V.; Averett, Devron R.;
 Koszalka,
 George W.
 CS Div. Exp. Therapy, Burroughs Wellcome Co., Research Triangle Park, NC,
 27709, USA
 SO Antimicrob. Agents Chemother. (1994), 38(4), 868-71
 CODEN: AMACCQ; ISSN: 0066-4804
 DT Journal
 LA English

 L10 ANSWER 159 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1993:93802 CAPLUS
 DN 118:93802
 TI The anti-**hepatitis** B virus activities, cytotoxicities, and
 anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-
 (hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
 AU Furman, Phillip A.; Davis, Michelle; Liotta, Dennis C.; Paff, Melanie;
 Frick, Lloyd W.; Nelson, Donald J.; Dornsife, Ronna E.; Wurster, J. A.;
 Wilson, Lawrence J.; et al.
 CS Div. Virol., Burroughs Wellcome Co., Research Triangle Park, NC, 27709,
 USA
 SO Antimicrob. Agents Chemother. (1992), 36(12), 2686-92
 CODEN: AMACCQ; ISSN: 0066-4804
 DT Journal
 LA English

 L10 ANSWER 160 OF 160 CAPLUS COPYRIGHT 2001 ACS
 AN 1992:194772 CAPLUS
 DN 116:194772
 TI Synthesis of enantiomerically pure (2'R,5'S)-(-)-1-(2-
 hydroxymethyloxathiolan-5-yl)cytosine as a potent **antiviral**
 agent against **hepatitis** B virus (HBV) and human
 immunodeficiency virus (HIV)
 AU Beach, J. Warren; Jeong, Lak S.; Alves, Antonio J.; Pohl, Douglas; Kim,
 Hea O.; Chang, Chien Neng; Doong, Shin Lian; Schinazi, Raymond F.; Cheng,
 Yung Chi; Chu, Chung K.
 CS Coll. Pharm., Univ. Georgia, Athens, GA, 30602, USA
 SO J. Org. Chem. (1992), 57(8), 2217-19
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal

LA English
OS CASREACT 116:194772

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1 32 S E1-E3

L2 10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3 31704 S E3

L4 4491 S HBV

L5 751 S L1

L6 1070 S L2

L7 16 S L5 AND L6

L8 271 S L6 AND L3

L9 176 S L8 AND L4

L10 160 S L9 AND ANTIVIRAL

=> s 15 and 13

L11 19 L5 AND L3

=> d l11 1-19

L11 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:677355 CAPLUS

DN 135:195748

TI Process for the synthesis of aza sugars having biological activity

IN Lopes, Claudio Cerqueira; Lopes, Rosangela Sabbatini Capella; Matos,
Carlos Roberto Ribeiro

PA Brazil

SO Braz. Pedido PI, 56 pp.

CODEN: BPXXDX

DT Patent

LA Portuguese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	BR 9902585	A	20000926	BR 1999-2585	19990211

L11 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:617821 CAPLUS

DN 135:175348

TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for
treating **hepatitis** virus infections

IN Mueller, Richard A.; Bryant, Martin L.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

LA English
OS CASREACT 116:194772

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1 32 S E1-E3

L2 10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3 31704 S E3

L4 4491 S HBV

L5 751 S L1

L6 1070 S L2

L7 16 S L5 AND L6

L8 271 S L6 AND L3

L9 176 S L8 AND L4

L10 160 S L9 AND ANTIVIRAL

=> s 15 and 13

L11 19 L5 AND L3

=> d l11 1-19

L11 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:677355 CAPLUS

DN 135:195748

TI Process for the synthesis of aza sugars having biological activity

IN Lopes, Claudio Cerqueira; Lopes, Rosangela Sabbatini Capella; Matos, Carlos Roberto Ribeiro

PA Brazil

SO Braz. Pedido PI, 56 pp.

CODEN: BPXXDX

DT Patent

LA Portuguese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	BR 9902585	A	20000926	BR 1999-2585	19990211

L11 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:617821 CAPLUS

DN 135:175348

TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating **hepatitis** virus infections

IN Mueller, Richard A.; Bryant, Martin L.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

 PI WO 2001060366 A1 20010823 WO 2001-US4512 20010213
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRAI US 2000-182362 P 20000214

RE.CNT 9

RE

- (1) Block, T; NATURE MEDICINE 1998, V4(5), P610 CAPLUS
 - (2) Block, T; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1994, V91(6), P2235 CAPLUS
 - (3) Dwek, R; WO 9835685 A 1998 CAPLUS
 - (4) Mueller, R; WO 9940916 A 1999 CAPLUS
 - (5) Mueller, R; WO 0047198 A 2000 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:338762 CAPLUS

DN 134:362292

TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

IN Farr, Spencer

PA Phase-1 Molecular Toxicology, USA

SO PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-165398	P	19991105		
	US 2000-196571	P	20000411		

L11 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:300514 CAPLUS

DN 134:331617

TI Oil-in-water emulsion compositions for polyfunctional active ingredients

IN Chen, Feng-jing; Patel, Mahesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

 PI WO 2001060366 A1 20010823 WO 2001-US4512 20010213
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRAI US 2000-182362 P 20000214

RE.CNT 9

RE

- (1) Block, T; NATURE MEDICINE 1998, V4(5), P610 CAPLUS
 - (2) Block, T; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1994, V91(6), P2235 CAPLUS
 - (3) Dwek, R; WO 9835685 A 1998 CAPLUS
 - (4) Mueller, R; WO 9940916 A 1999 CAPLUS
 - (5) Mueller, R; WO 0047198 A 2000 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:338762 CAPLUS

DN 134:362292

TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

IN Farr, Spencer

PA Phase-1 Molecular Toxicology, USA

SO PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-165398	P	19991105		
	US 2000-196571	P	20000411		

L11 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:300514 CAPLUS

DN 134:331617

TI Oil-in-water emulsion compositions for polyfunctional active ingredients

IN Chen, Feng-jing; Patel, Mahesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028555	A1	20010426	WO 2000-US28835	20001018
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-420159 A 19991018

RE.CNT 6

RE

- (1) Bistriani; US 4871768 A 1989 CAPLUS
- (2) Demichele; US 5661180 A 1997 CAPLUS
- (3) Demichele; US 6013665 A 2000 CAPLUS
- (4) Demichele; US 6130244 A 2000 CAPLUS
- (5) Demichele; US 6160007 A 2000 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:114972 CAPLUS

DN 134:163282

TI Preparation of long chain N-alkyl amino and imino alditols and oxa-derivatives as antiviral agents

IN Zitzmann, Nicole; Butters, Terry D.; Platt, Frances M.; Carrouee, Sandra; Jacob, Gary S.; Picker, Donald H.; Fleet, George W. J.; Dwek, Raymond A.

PA UK

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010429	A2	20010215	WO 2000-US21732	20000810
	WO 2001010429	A3	20010816		
	W:	AU, BR, CA, CN, IN, JP, KR, US			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	AU 2001018401	A5	20010305	AU 2001-18401	20000810
PRAI	US 1999-148101	P	19990810		
	US 2000-198621	P	20000420		
	WO 2000-US21732	W	20000810		
OS	MARPAT 134:163282				

L11 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:100967 CAPLUS

DN 134:141721

TI N-Substituted glucamine compounds for treating hepatitis virus infections

IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 148 pp.

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028555	A1	20010426	WO 2000-US28835	20001018
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1999-420159 A 19991018

RE.CNT 6

RE

(1) Bistrrian; US 4871768 A 1989 CAPLUS

(2) Demichele; US 5661180 A 1997 CAPLUS

(3) Demichele; US 6013665 A 2000 CAPLUS

(4) Demichele; US 6130244 A 2000 CAPLUS

(5) Demichele; US 6160007 A 2000 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:114972 CAPLUS

DN 134:163282

TI Preparation of long chain N-alkyl amino and imino alditols and oxa-derivatives as antiviral agents

IN Zitzmann, Nicole; Butters, Terry D.; Platt, Frances M.; Carrouee, Sandra; Jacob, Gary S.; Picker, Donald H.; Fleet, George W. J.; Dwek, Raymond A.

PA UK

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010429	A2	20010215	WO 2000-US21732	20000810
	WO 2001010429	A3	20010816		
	W: AU, BR, CA, CN, IN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 2001018401	A5	20010305	AU 2001-18401	20000810
PRAI	US 1999-148101	P	19990810		
	US 2000-198621	P	20000420		
	WO 2000-US21732	W	20000810		
OS	MARPAT 134:163282				

L11 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:100967 CAPLUS

DN 134:141721

TI N-Substituted glucamine compounds for treating **hepatitis** virus infections

IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 148 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008672	A2	20010208	WO 2000-US3816	20000214
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-119836	P	19990212		
	US 1999-119858	P	19990212		
OS	MARPAT 134:141721				

L11 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:573657 CAPLUS

DN 133:172150

TI Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating

hepatitis virus infections

IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 170 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047198	A2	20000817	WO 2000-US3768	20000214
	WO 2000047198	A3	20010215		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-119722	P	19990212		
	US 1999-119856	P	19990212		
OS	MARPAT 133:172150				

L11 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:545931 CAPLUS

DN 133:346609

TI High-Performance Cation-Exchange Chromatography and Pulsed Amperometric Detection for the Separation, Detection, and Quantitation of N-Alkylated Imino Sugars in Biological Samples

AU Mellor, H. R.; Adam, A.; Platt, F. M.; Dwek, R. A.; Butters, T. D.

CS Oxford Glycobiology Institute, Dep. Biochem., University of Oxford,

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008672	A2	20010208	WO 2000-US3816	20000214
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-119836	P	19990212		
	US 1999-119858	P	19990212		
OS	MARPAT 134:141721				

L11 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:573657 CAPLUS

DN 133:172150

TI Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating

hepatitis virus infections

IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 170 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047198	A2	20000817	WO 2000-US3768	20000214
	WO 2000047198	A3	20010215		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-119722	P	19990212		
	US 1999-119856	P	19990212		
OS	MARPAT 133:172150				

L11 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:545931 CAPLUS

DN 133:346609

TI High-Performance Cation-Exchange Chromatography and Pulsed Amperometric Detection for the Separation, Detection, and Quantitation of N-Alkylated Imino Sugars in Biological Samples

AU Mellor, H. R.; Adam, A.; Platt, F. M.; Dwek, R. A.; Butters, T. D.

CS Oxford Glycobiology Institute, Dep. Biochem., University of Oxford,

Oxford, OX1 3QU, UK
SO Anal. Biochem. (2000), 284(1), 136-142
CODEN: ANBCA2; ISSN: 0003-2697

PB Academic Press

DT Journal

LA English

RE.CNT 14

RE

- (1) Andersson, U; Biochem Pharmacol 2000, V59, P821 CAPLUS
- (2) Block, T; Nature Med 1998, V4, P610 CAPLUS
- (3) Butters, T; Tetrahedron: Asymmetry 2000, V11, P113 CAPLUS
- (4) Hardy, M; Proc Natl Acad Sci USA 1988, V85, P3289 CAPLUS
- (5) Jeyakumar, M; Proc Natl Acad Sci USA 1999, V96, P6388 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:172843 CAPLUS

DN 132:175813

TI Method using an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol
for

inhibiting **hepatitis** B virus

IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.

PA G. D. Searle & Co., USA

SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 181,519, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6037351	A	20000314	US 1996-676153	19960711
	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		

RE.CNT 21

RE

- (1) Block; Proc Natl Acad Sci USA 1994, V91, P2235 CAPLUS
- (3) Fleet; US 4849430 1989 CAPLUS
- (4) Fleet; FEBS Lett 1988, V237, P128 CAPLUS
- (5) Ganem; Chemtracts:Organic Chem 1994, V7(2), P106 CAPLUS
- (10) Jacob; US 4957926 1990 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1999:685007 CAPLUS

DN 132:18513

TI Imino sugars inhibit the formation and secretion of bovine viral diarrhea
virus, a pestivirus model of **hepatitis** C virus: implications for
the development of broad spectrum anti-**hepatitis** virus agents

AU Zitzmann, Nicole; Mehta, Anand S.; Carrouee, Sandra; Butters, Terry D.;
Platt, Frances M.; McCauley, John; Blumberg, Baruch S.; Dwek, Raymond A.;

Oxford, OX1 3QU, UK
SO Anal. Biochem. (2000), 284(1), 136-142
CODEN: ANBCA2; ISSN: 0003-2697

PB Academic Press

DT Journal

LA English

RE.CNT 14

RE

- (1) Andersson, U; Biochem Pharmacol 2000, V59, P821 CAPLUS
- (2) Block, T; Nature Med 1998, V4, P610 CAPLUS
- (3) Butters, T; Tetrahedron: Asymmetry 2000, V11, P113 CAPLUS
- (4) Hardy, M; Proc Natl Acad Sci USA 1988, V85, P3289 CAPLUS
- (5) Jeyakumar, M; Proc Natl Acad Sci USA 1999, V96, P6388 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:172843 CAPLUS

DN 132:175813

TI Method using an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol
for

inhibiting **hepatitis** B virus

IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.

PA G. D. Searle & Co., USA

SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 181,519, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6037351	A	20000314	US 1996-676153	19960711
	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		

RE.CNT 21

RE

- (1) Block; Proc Natl Acad Sci USA 1994, V91, P2235 CAPLUS
- (3) Fleet; US 4849430 1989 CAPLUS
- (4) Fleet; FEBS Lett 1988, V237, P128 CAPLUS
- (5) Ganem; Chemtracts:Organic Chem 1994, V7(2), P106 CAPLUS
- (10) Jacob; US 4957926 1990 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1999:685007 CAPLUS

DN 132:18513

TI Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of **hepatitis** C virus: implications for the development of broad spectrum anti-**hepatitis** virus agents

AU Zitzmann, Nicole; Mehta, Anand S.; Carrouee, Sandra; Butters, Terry D.; Platt, Frances M.; McCauley, John; Blumberg, Baruch S.; Dwek, Raymond A.;

Block, Timothy M.
 CS The Glycobiology Institute, Department of Biochemistry, Oxford
 University,
 Oxford, OX1 3QU, UK
 SO Proc. Natl. Acad. Sci. U. S. A. (1999), 96(21), 11878-11882
 CODEN: PNASA6; ISSN: 0027-8424
 PB National Academy of Sciences
 DT Journal
 LA English
 RE.CNT 21
 RE

- (2) Block, T; Nat Med 1998, V4, P610 CAPLUS
 - (3) Block, T; Proc Natl Acad Sci USA 1994, V91, P2235 CAPLUS
 - (4) Chambers, T; Annu Rev Microbiol 1990, V44, P649 CAPLUS
 - (5) Choukhi, A; J Virol 1998, V72, P3851 CAPLUS
 - (7) Dubuisson, J; J Virol 1994, V68, P6147 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2001 ACS
 AN 1999:529023 CAPLUS
 DN 131:165293
 TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for
 treating **hepatitis** virus infections
 IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.
 PA G.D. Searle & Co., USA
 SO PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940916	A1	19990819	WO 1999-US1874	19990212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9927595	A1	19990830	AU 1999-27595	19990212
	BR 9907882	A	20001017	BR 1999-7882	19990212
	EP 1061922	A1	20001227	EP 1999-908079	19990212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI					
PRAI	US 1998-23401	A	19980212		
	US 1998-74508	P	19980212		
	WO 1999-US1874	W	19990212		
OS	MARPAT 131:165293				

RE.CNT 9
 RE
 (1) Bayer AG; EP 0449026 A 1991 CAPLUS
 (3) G D Searle & Co; WO 9522975 A 1995 CAPLUS
 (4) G D Searle & Co; EP 0367748 A 1990 CAPLUS
 (5) G D Searle and Co; WO 9835685 A 1998 CAPLUS
 (6) Meiji Seika Kaisha Ltd; EP 0350012 A 1990 CAPLUS

Block, Timothy M.
CS The Glycobiology Institute, Department of Biochemistry, Oxford
University,

Oxford, OX1 3QU, UK

SO Proc. Natl. Acad. Sci. U. S. A. (1999), 96(21), 11878-11882

CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences

DT Journal

LA English

RE.CNT 21

RE

(2) Block, T; Nat Med 1998, V4, P610 CAPLUS

(3) Block, T; Proc Natl Acad Sci USA 1994, V91, P2235 CAPLUS

(4) Chambers, T; Annu Rev Microbiol 1990, V44, P649 CAPLUS

(5) Choukhi, A; J Virol 1998, V72, P3851 CAPLUS

(7) Dubuisson, J; J Virol 1994, V68, P6147 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1999:529023 CAPLUS

DN 131:165293

TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for
treating **hepatitis** virus infections

IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	----	-----	-----
PI	WO 9940916	A1	19990819	WO 1999-US1874	19990212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,				
	KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,				
	MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,				
	TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,				
	TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9927595	A1	19990830	AU 1999-27595	19990212
	BR 9907882	A	20001017	BR 1999-7882	19990212
	EP 1061922	A1	20001227	EP 1999-908079	19990212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

FI

PRAI US 1998-23401 A 19980212

US 1998-74508 P 19980212

WO 1999-US1874 W 19990212

OS MARPAT 131:165293

RE.CNT 9

RE

(1) Bayer AG; EP 0449026 A 1991 CAPLUS

(3) G D Searle & Co; WO 9522975 A 1995 CAPLUS

(4) G D Searle & Co; EP 0367748 A 1990 CAPLUS

(5) G D Searle and Co; WO 9835685 A 1998 CAPLUS

(6) Meiji Seika Kaisha Ltd; EP 0350012 A 1990 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1999:390377 CAPLUS

DN 131:39716

TI Glucosidase or glucosyltransferase inhibitors for inhibition of
membrane-associated viral replication and treatment of lipid storage
diseasesIN Blumberg, Baruch S.; Block, Timothy M.; Dwek, Raymond A.; Mehta, Anand;
Platt, Frances; Butters, Terry D.; Zitzmann, NicolePA The Chancellor, Masters and Scholars of the University of Oxford, UK;
Thomas Jefferson University

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929321	A1	19990617	WO 1998-US26241	19981210
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9917215	A1	19990628	AU 1999-17215	19981210
	EP 1037636	A1	20000927	EP 1998-962046	19981210
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	BR 9813508	A	20001003	BR 1998-13508	19981210
PRAI	US 1997-69245	P	19971211		
	WO 1998-US26241	W	19981210		

OS MARPAT 131:39716

RE.CNT 2

RE

(1) Bryant; US 5622972 A 1997 CAPLUS

(2) Rohrschneider; US 5643888 A 1997 CAPLUS

L11 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1998:568726 CAPLUS

DN 129:197981

TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in
combination therapy for treating **hepatitis** virus infections

IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,			

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1999:390377 CAPLUS

DN 131:39716

TI Glucosidase or glucosyltransferase inhibitors for inhibition of membrane-associated viral replication and treatment of lipid storage diseases

IN Blumberg, Baruch S.; Block, Timothy M.; Dwek, Raymond A.; Mehta, Anand; Platt, Frances; Butters, Terry D.; Zitzmann, Nicole

PA The Chancellor, Masters and Scholars of the University of Oxford, UK; Thomas Jefferson University

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929321	A1	19990617	WO 1998-US26241	19981210
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9917215	A1	19990628	AU 1999-17215	19981210
	EP 1037636	A1	20000927	EP 1998-962046	19981210
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	BR 9813508	A	20001003	BR 1998-13508	19981210
PRAI	US 1997-69245	P	19971211		
	WO 1998-US26241	W	19981210		

OS MARPAT 131:39716

RE.CNT 2

RE

(1) Bryant; US 5622972 A 1997 CAPLUS

(2) Rohrschneider; US 5643888 A 1997 CAPLUS

L11 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1998:568726 CAPLUS

DN 129:197981

TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy for treating **hepatitis** virus infections

IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,			

DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,
 UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG
 AU 9861692 A1 19980908 AU 1998-61692 19980212
 EP 1007058 A1 20000614 EP 1998-906475 19980212
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
 FI
 JP 2001512462 T2 20010821 JP 1998-535987 19980212
 PRAI US 1997-41221 P 19970214
 WO 1998-US3004 W 19980212
 OS MARPAT 129:197981

 L11 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2001 ACS
 AN 1996:676601 CAPLUS
 DN 126:166108
 TI Copper(II) interactions with an experimental antiviral agent,
 1-deoxynojirimycin, and oxygen activation by resulting complexes
 AU Jezowska-Bojczuk, Malgorzata; Bal, Wojciech; Kasprzak, Kazimierz S.
 CS Faculty of Chemistry, University of Wroclaw, Wroclaw, 50-383, Pol.
 SO J. Inorg. Biochem. (1996), 64(4), 231-246
 CODEN: JIBIDJ; ISSN: 0162-0134
 PB Elsevier
 DT Journal
 LA English

 L11 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2001 ACS
 AN 1996:385934 CAPLUS
 DN 125:41767
 TI Synthesis and formulation of triazine derivatives as **hepatitis**
 remedies
 IN Ueda, Fusao; Ozaki, Takayuki; Nakamura, Ken-ichi
 PA Nippon Shinyaku Co., Ltd., Japan
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9604914	A1	19960222	WO 1995-JP1577	19950808
	W: AU, BR, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2197091	AA	19960222	CA 1995-2197091	19950808
	AU 9531920	A1	19960307	AU 1995-31920	19950808
	AU 703263	B2	19990325		
	EP 775487	A1	19970528	EP 1995-927992	19950808
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
	CN 1155244	A	19970723	CN 1995-194521	19950808
	BR 9508539	A	19971028	BR 1995-8539	19950808
	HU 77735	A2	19980728	HU 1997-355	19950808
	RU 2147233	C1	20000410	RU 1997-103983	19950808
	US 5962453	A	19991005	US 1997-776992	19970206
PRAI	JP 1994-185810	A	19940808		
	WO 1995-JP1577	W	19950808		

DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,
 UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG
 AU 9861692 A1 19980908 AU 1998-61692 19980212
 EP 1007058 A1 20000614 EP 1998-906475 19980212
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
 FI JP 2001512462 T2 20010821 JP 1998-535987 19980212
 PRAI US 1997-41221 P 19970214
 WO 1998-US3004 W 19980212
 OS MARPAT 129:197981

L11 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2001 ACS
 AN 1996:676601 CAPLUS
 DN 126:166108
 TI Copper(II) interactions with an experimental antiviral agent,
 l-deoxynojirimycin, and oxygen activation by resulting complexes
 AU Jezowska-Bojczuk, Malgorzata; Bal, Wojciech; Kasprzak, Kazimierz S.
 CS Faculty of Chemistry, University of Wroclaw, Wroclaw, 50-383, Pol.
 SO J. Inorg. Biochem. (1996), 64(4), 231-246
 CODEN: JIBIDJ; ISSN: 0162-0134
 PB Elsevier
 DT Journal
 LA English

L11 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2001 ACS
 AN 1996:385934 CAPLUS
 DN 125:41767
 TI Synthesis and formulation of triazine derivatives as **hepatitis**
 remedies
 IN Ueda, Fusao; Ozaki, Takayuki; Nakamura, Ken-ichi
 PA Nippon Shinyaku Co., Ltd., Japan
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9604914	A1	19960222	WO 1995-JP1577	19950808
	W: AU, BR, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2197091	AA	19960222	CA 1995-2197091	19950808
	AU 9531920	A1	19960307	AU 1995-31920	19950808
	AU 703263	B2	19990325		
	EP 775487	A1	19970528	EP 1995-927992	19950808
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
	CN 1155244	A	19970723	CN 1995-194521	19950808
	BR 9508539	A	19971028	BR 1995-8539	19950808
	HU 77735	A2	19980728	HU 1997-355	19950808
	RU 2147233	C1	20000410	RU 1997-103983	19950808
	US 5962453	A	19991005	US 1997-776992	19970206
PRAI	JP 1994-185810	A	19940808		
	WO 1995-JP1577	W	19950808		

OS MARPAT 125:41767

L11 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1995:785110 CAPLUS

DN 123:160827

TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of **hepatitis** B virus infections

IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.

PA G.D. Searle and Co., USA; Monsanto Co.

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,			
VN		RW:	KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		

L11 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1994:671340 CAPLUS

DN 121:271340

TI N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. Secretion of human **hepatitis** B virus is inhibited by the imino sugar N-butyldeoxynojirimycin

AU Ganem, Bruce

CS Cornell Univ., USA

SO Chemtracts: Org. Chem. (1994), 7(2), 106-7

CODEN: CMOCEI; ISSN: 0895-4445

DT Journal

LA English

L11 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1994:235511 CAPLUS

DN 120:235511

TI Secretion of human **hepatitis** B virus is inhibited by the imino sugar N-butyldeoxynojirimycin

AU Block, Timothy M.; Lu, Xuanyong; Platt, Frances M.; Foster, Graham R.; Gerlich, Wolfram H.; Blumberg, Baruch S.; Dwek, Raymond A.

CS Jefferson Cancer Inst., Jefferson Med. Coll., Philadelphia, PA, 19107, USA

OS MARPAT 125:41767

L11 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1995:785110 CAPLUS

DN 123:160827

TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of **hepatitis** B virus infections

IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.

PA G.D. Searle and Co., USA; Monsanto Co.

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN					
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		

L11 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1994:671340 CAPLUS

DN 121:271340

TI N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. Secretion of human **hepatitis** B virus is inhibited by the imino sugar N-butyldeoxynojirimycin

AU Ganem, Bruce

CS Cornell Univ., USA

SO Chemtracts: Org. Chem. (1994), 7(2), 106-7

CODEN: CMOCEI; ISSN: 0895-4445

DT Journal

LA English

L11 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1994:235511 CAPLUS

DN 120:235511

TI Secretion of human **hepatitis** B virus is inhibited by the imino sugar N-butyldeoxynojirimycin

AU Block, Timothy M.; Lu, Xuanyong; Platt, Frances M.; Foster, Graham R.; Gerlich, Wolfram H.; Blumberg, Baruch S.; Dwek, Raymond A.

CS Jefferson Cancer Inst., Jefferson Med. Coll., Philadelphia, PA, 19107, USA

SO Proc. Natl. Acad. Sci. U. S. A. (1994), 91(6), 2235-9
CODEN: PNASA6; ISSN: 0027-8424
DT Journal
LA English

L11 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2001 ACS
AN 1985:592966 CAPLUS
DN 103:192966
TI The effects of processing inhibitors of N-linked oligosaccharides on the intracellular migration of glycoprotein E2 of mouse **hepatitis** virus and the maturation of coronavirus particles
AU Repp, Reinald; Tamura, Teruko; Boschek, C. Bruce; Wege, H.; Schwarz, Ralph
T.; Niemann, Heiner
CS Inst. Med. Virol., Justus-Liebig-Univ., Giessen, D-6300, Fed. Rep. Ger.
SO J. Biol. Chem. (1985), 260(29), 15873-9
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English

=> d l11 16 all

L11 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2001 ACS
AN 1995:785110 CAPLUS
DN 123:160827
TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of **hepatitis** B virus infections
IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.
PA G.D. Searle and Co., USA; Monsanto Co.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-445
CC 1-5 (Pharmacology)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		

SO Proc. Natl. Acad. Sci. U. S. A. (1994), 91(6), 2235-9
 CODEN: PNASA6; ISSN: 0027-8424

DT Journal
 LA English

L11 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2001 ACS
 AN 1985:592966 CAPLUS
 DN 103:192966
 TI The effects of processing inhibitors of N-linked oligosaccharides on the
 intracellular migration of glycoprotein E2 of mouse **hepatitis**
 virus and the maturation of coronavirus particles
 AU Repp, Reinald; Tamura, Teruko; Boschek, C. Bruce; Wege, H.; Schwarz,
 Ralph
 T.; Niemann, Heiner
 CS Inst. Med. Virol., Justus-Liebig-Univ., Giessen, D-6300, Fed. Rep. Ger.
 SO J. Biol. Chem. (1985), 260(29), 15873-9
 CODEN: JBCHA3; ISSN: 0021-9258

DT Journal
 LA English

=> d l11 16 all

L11 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2001 ACS
 AN 1995:785110 CAPLUS
 DN 123:160827
 TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the
 treatment of **hepatitis** B virus infections
 IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.
 PA G.D. Searle and Co., USA; Monsanto Co.
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 IC ICM A61K031-445
 CC 1-5 (Pharmacology)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		

WO 1994-US14548 19941223

AB A method is disclosed for the treatment of **hepatitis B** virus (HBV) infections, which comprises administering to the infected host an N-alkyl deriv. of 1,5-dideoxy-1,5-imido-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms. In examples, N-butyl-1,5-dideoxy-1,5-imino-D-glucitol was shown to suppress the secretion of HBV particles and to cause intracellular retention of HBV

DNA in both stably transfected HepG 2.2.15 cells and HBV-infected HepG 2 cells.

ST deoxynojirimycin deriv virucide **hepatitis B**

IT Virucides and Virustats
 (deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

IT Virus, animal
 (**hepatitis B**, deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

IT 72599-27-0, N-Butyl 1-deoxynojirimycin
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1 32 S E1-E3

L2 10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3 31704 S E3

L4 4491 S HBV

L5 751 S L1

L6 1070 S L2

L7 16 S L5 AND L6

L8 271 S L6 AND L3

L9 176 S L8 AND L4

L10 160 S L9 AND ANTIVIRAL

L11 19 S L5 AND L3

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

WO 1994-US14548 19941223

AB A method is disclosed for the treatment of **hepatitis B** virus (HBV) infections, which comprises administering to the infected host an N-alkyl deriv. of 1,5-dideoxy-1,5-imido-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms. In examples, N-butyl-1,5-dideoxy-1,5-imino-D-glucitol was shown to suppress the secretion of HBV particles and to cause intracellular retention of HBV

DNA in both stably transfected HepG 2.2.15 cells and HBV-infected HepG 2 cells.

ST deoxynojirimycin deriv virucide **hepatitis B**

IT Virucides and Virustats
 (deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

IT Virus, animal
 (**hepatitis B**, deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

IT **72599-27-0**, N-Butyl 1-deoxynojirimycin
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1 32 S E1-E3

L2 10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3 31704 S E3

L4 4491 S HBV

L5 751 S L1

L6 1070 S L2

L7 16 S L5 AND L6

L8 271 S L6 AND L3

L9 176 S L8 AND L4

L10 160 S L9 AND ANTIVIRAL

L11 19 S L5 AND L3

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST	ENTRY 98.29	SESSION 119.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.35	-2.35

Dear valued customer,

Your feedback is important to us. Would you kindly take a moment to complete our survey? This survey will only take about 5-10 minutes to complete. Your responses will be kept confidential and will help us improve STN Express with Discover! for your future use. Please click on the following link to access the survey.

<http://www.cas.org/ONLINE/STN/ExpressSurveyForm.html?LOGINID=SSSPTAU125RXT>

STN INTERNATIONAL LOGOFF AT 12:13:32 ON 27 SEP 2001

FULL ESTIMATED COST	ENTRY	SESSION
	98.29	119.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.35	-2.35

Dear valued customer,

Your feedback is important to us. Would you kindly take a moment to complete our survey? This survey will only take about 5-10 minutes to complete. Your responses will be kept confidential and will help us improve STN Express with Discover! for your future use. Please click on the following link to access the survey.

<http://www.cas.org/ONLINE/STN/ExpressSurveyForm.html?LOGINID=SSSPTAU125RXT>

STN INTERNATIONAL LOGOFF AT 12:13:32 ON 27 SEP 2001